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Angelina M. Hernández-Carretero 
Novel Roles of p21 in Apoptosis During Beta Cell Stress in Diabetes 
Type 2 diabetes manifests from peripheral insulin resistance and a loss of 
functional beta cell mass due to decreased beta cell function, survival, and/or 
proliferation. Beta cell  stressors impair each of these factors by activating stress 
response mechanisms, including endoplasmic reticulum (ER) stress. The 
glucolipotoxic environment of the diabetic milieu also activates a stress response 
in beta cells, resulting in death and decreased survival. Whereas the cell cycle 
machinery (comprised of cyclins, kinases, and inhibitors) regulates proliferation, 
its involvement during beta cell stress in the development of diabetes is not well 
understood. Interestingly, in a screen of multiple cell cycle inhibitors, p21 was 
dramatically upregulated in INS-1-derived 832/13 cells and rodent islets by two 
independent pharmacologic inducers of beta cell stress - dexamethasone and 
thapsigargin. In addition, glucolipotoxic stress mimicking the diabetic milieu also 
induced p21. To further investigate p21’s role in the beta cell, p21 was 
adenovirally overexpressed in 832/13 cells and rat islets. As expected given 
p21’s role as a cell cycle inhibitor, p21 overexpression decreased [3H]-thymidine 
incorporation and blocked the G1/S and G2/M transitions as quantified by flow 
cytometry. Interestingly, p21 overexpression activated apoptosis, demonstrated 
by increased annexin- and propidium iodide-double-positive cells and cleaved 
caspase-3 protein. p21-mediated caspase-3 cleavage was inhibited by either 
overexpression of the anti-apoptotic mitochondrial protein Bcl-2 or siRNA-
mediated suppression of the pro-apoptotic proteins Bax and Bak. Therefore, the 
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intrinsic apoptotic pathway is central for p21-mediated cell death. Like 
glucolipotoxicity, p21 overexpression inhibited the insulin cell survival signaling 
pathway while also impairing glucose-stimulated insulin secretion, an index of 
beta cell function. Under both conditions, phosphorylation of insulin receptor 
substrate-1, Akt, and Forkhead box protein-O1 was reduced. p21 overexpression 
increased Bim and c-Jun N-terminal Kinase, however, siRNA-mediated reduction 
or inhibition of either protein, respectively, did not alter p21-mediated cell death. 
Importantly, islets of p21-knockout mice treated with the ER stress inducer 
thapsigargin displayed a blunted apoptotic response. In summary, our findings 
indicate that p21 decreases proliferation, activates apoptosis, and impairs beta 
cell function, thus being a potential target to inhibit for the protection of functional 
beta cell mass. 
                            
                   Patrick T. Fueger, Ph.D., Chair 
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Chapter I. Introduction 
 
I.A. Type 2 diabetes and obesity 
Approximately 29 million people (or 9% of the population) in the United 
States (US) have diabetes, and the incidence of this devastating disease has 
increased drastically in the last couple decades, following a similar trend as the 
rise in the rate of obesity (Centers for Disease Control and Prevention 2014, 
2012, Ogden et al. 2014). Within a 16-year timeframe (1994-2010), the 
percentage of newly diagnosed patients with diabetes who were also overweight 
or obese increased from 69.7 to 84.7% (Centers for Disease Control and 
Prevention 2011). In fact, the Centers for Disease Control and Prevention (CDC) 
recently proposed that 40% of the US population will develop diabetes in their 
lifetime.  Interestingly, the prevalence of diabetes is greater amongst African 
American, Hispanic, and Native American populations, with a prediction by the 
CDC that half of African American women and Hispanic men and women will 
develop diabetes (Centers for Disease Control and Prevention 2012). This 
“diabesity” epidemic has also spread across the world in many developing and 
developed nations. 
The estimated national cost of diagnosed diabetes in 2012 was $245 
billion, incuding both direct medical costs (72%) and lost productivity (28%) such 
as unemployment from chronic disability, premature mortality, or reduced 
productivity at work and home (American Diabetes Association 2013). Type 2 
diabetes (T2D), the predominant form of diabetes, contributes to metabolic 
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syndrome and is known to increase health complications, including 
cardiovascular disease, renal failure, neuropathy, retinopathy, and limb 
amputations. In fact, according to the CDC, diabetes remains as one of the 
leading causes of death in the US, and was noted as the 7th leading cause in 
2010 (Centers for Disease Control and Prevention 2014). 
Although genetics predispose someone to developing T2D, the major 
reasons behind the recent rise in the disease are most likely explained by 
environmental factors, such as excessive caloric intake of food sources with poor 
nutritional value and more sedentary lifestyle choices that promote excessive fat 
storage. Currently, it is estimated that about 35% of US adults are obese, and the 
national map of its prevalence is tightly correlated with the national map for the 
prevalence of diabetes (Ogden et al. 2014, Ogden et al. 2010, Centers for 
Disease Control and Prevention 2011). A major outcome of obesity is insulin 
resistance, and both of these co-factors contribute to an increased risk of pre-
diabetes and T2D. About 90-95% of diabetes cases are T2D, and even more 
disturbing is that today 35% of adults above age 20 in the US are pre-diabetic 
(with a fasting blood glucose level between 100 to 125 mg/dL) (Cowie et al. 
2009, Geiss et al. 2010, James et al. 2011, American Diabetes Association 
2012). 
Diabetes is a disease of misregulated glucose homeostasis. After a meal 
in normal, healthy individuals, nutrients and metabolic signals traverse to the 
pancreas, which is comprised of the endocrine Islets of Langerhans within the 
exocrine acinar tissue. Specifically, glucose signals the beta-cells within the 
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islets, via specific glucose-sensing machinery within the cell, to secrete insulin 
into the circulation to stimulate glucose disposal by peripheral tissues, including 
muscle, liver, and adipose tissue. In addtion, hormonal factors secreted in 
response to nutrient ingestion such as the incretin GLP-1 potentiate insulin 
secretion.  However, with insulin resistance, these signals are markedly 
diminished. In an effort to combat insulin resistance, the pancreatic beta cells 
compensate by increasing their insulin output, which is dependent on an 
expansion of beta cell mass and enhanced function. The compensatory 
responses for the increased demand for insulin production and secretion can 
activate stress responses that ultimately result in the demise of the pancreatic 
beta cells, which are pathologically targeted in both major forms of diabetes – 
type 1 and type 2.  
Currently, there are interventions to delay the clinical onset of diabetes. 
Namely, dietary restrictions in combination with exercise are known to prevent 
pre-diabetic patients from transitioning to frank T2D, or fasting blood glucose 
levels equal to or above 126 mg/dL (American Diabetes Association 2012). 
However, patient compliance of this therapeutic intervention limits the efficacy of 
this approach. Finding a therapeutic treatment that will completely inhibit the 
decline of functioning beta cells would prove beneficial to reduce the prevalence 
and severity of diabetes.  
In the following subsections, I will describe the beta cell-centric 
perspective for the cause of diabetes by discussing the beta cell defects 
occurring in diabetic individuals, the pathological stressors that target the beta 
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cell, the stress response mechanisms of the beta cell, and the role of the cell 
cycle machinery during stress, especially with regards to the cyclin-dependent 
kinase inhibitor 1a, or p21. Chapters III and IV will detail my thesis research 
findings regarding a novel role for p21 in activating the instrinsic apoptosis 
pathway in beta cells, and insights into the molecular mechanisms by which p21 
is inducing beta cell death during stress (Hernandez et al. 2013). Finally, Chapter 
V will highlight p21 as a potential therapeutic target to limit the beta cell defects in 
diabetes and future studies required to fully elucidate the cellular mechanisms 
behind p21’s deleterious effects on the beta cell. 
 
I.B. Functional beta cell mass 
Functional beta cell mass, which incorporates both beta cell mass and 
beta cell function, is influenced by a number of processes including insulin 
secretion capacity, rate of proliferation/expansion of beta cells, other 
mechanisms that increase beta cell number or size, and rate of cell death 
(Figure 1).  The beta cell defects that occur in T2D are due to a decline in both 
beta cell function and beta cell mass – i.e., a composite fall in functional beta cell 
mass. In regards to beta cell function, impairments in first phase insulin secretion 
are evident in patients with overt type 2 diabetes and prediabetes (Kanat et al. 
2011, Cheng, Andrikopoulos, and Gunton 2013) . For beta cell mass, autopsy 
studies of individuals with diabetes and pre-diabetes with impaired fasting 
glucose provide evidence for a reduction in pancreatic beta cell mass 
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(Matveyenko and Butler 2008, Yoon et al. 2003, Kloppel et al. 1985, Butler et al. 
2003).  
Changes in beta cell mass occur through various mechanisms in order to 
adapt to the cellular and organismal environment. Increased regeneration and 
replication of existing beta cells are mechanisms that positively impact beta cell 
mass (Migliorini, Bader, and Lickert 2014, Dor et al. 2004). Neogenesis from 
neurogenin3+ ductal progenitors, regeneration of intra-islet multipotent 
pancreatic progenitors, or conversion of acinar cells into beta-like cells are all 
potential ways to regenerate beta-cells (Migliorini, Bader, and Lickert 2014). 
However, with aging, the replication and regeneration capacites of beta cells 
dramatically decline and are at very low levels post-natally (about less than 
0.07% of human beta cells undergo BrdU+ proliferation) (Teta et al. 2005). 
Furthermore, dedifferentiation and apoptosis negatively affect beta cell mass. 
Recently, dedifferentiation has been brought to light where during beta cell 
stress, beta cells dedifferentiate into a progenitor state that then is stimulated to 
differentiate into glucagon-secreting alpha cells of pancreatic islets (Talchai et al. 
2012). This mechanism could contribute to the decline in total overall beta cell 
mass in T2D. Similarly, apoptosis or beta cell death are stimulated by various 
cellular stressors and also contributes to the decline in mass. In theory, finding 
methods to inhibit dedifferentiation and apoptosis, while at the same time 
increase replication, neogenesis, or regeneration of beta cells will preserve or 
enhance beta cell mass. 
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Aside from preserving beta cell mass, it is equally essential to maintain or 
enhance beta cell function to prevent diabetes and diabetes-related secondary 
complications. Changes in glucose sensing, pulsatile insulin secretion, glucose-
stimulated insulin secretion (GSIS), proinsulin processing, and/or expression of 
genes and proteins required for insulin production, folding, and/or release impact 
beta cell function. Strong evidence suggests that an impairment in GSIS is 
evident long before the progression to full-blown diabetes (Ferrannini et al. 2005, 
Ferrannini et al. 2013). Factors, such as hyperglycemia, that constantly stimulate 
depletion of insulin granules lead to a loss of early phase insulin secretion, thus, 
negatively impacting beta cell function.  
During the progression to T2D, when peripheral tissues are insulin 
resistant, beta cell compensation occurs to maintain normoglycemia with the 
increased demand for insulin. This phase is characterized by hyperinsulinemia as 
a result of increased beta cell mass and/or functional capacity. Yet, eventually 
over time, the beta cells can no longer keep pace with the high insulin demand 
and undergo a switch to decompensation where beta cells begin to undergo cell 
stress, functional failure, and ultimately death. As the decompensation phase 
progresses, functional beta cell mass declines resulting in glucose intolerance 
and hyperglycemia, both characteristics of T2D. 
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Figure 1. 
 
Figure 1. Overview of the regulation of functional beta cell mass. Pancreatic 
beta cell mass is negatively regulated by beta cell death, dedifferentiation, and 
transdifferentiation. On the other hand, positive influence on beta cell mass 
include neogenesis, transdifferentiation of other endocrine or exocrine cell types, 
replication of pre-existing beta cells, and hyperplasia. 
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I.C. Beta cell stress in diabetes 
The overall research goal of my thesis work is to discover mechanisms 
that fortify functional beta cell mass. One way to achieve these goals is by 
studying molecular mechanisms that promote the switch between the 
compensation and decompensation phases. Some postulated mechanisms of 
beta cell destruction that promote this decompensation switch include stressors 
that directly act on the beta cells, such as human islet amyloid peptide, 
inflammatory cytokines, glucocorticoids, reactive oxygen species, high 
concentrations of glucose, or glucolipotoxicity, all of which are elevated in obese 
or diabetic individuals and are thought to contribute to the decline in functional 
beta cell mass (Kitamura 2013, Halban et al. 2014, Surampudi, John-Kalarickal, 
and Fonseca 2009). The islet responds to these stressors by activating cellular 
mechanisms that primarily work to alleviate or repair the negative effects of the 
stressors (summarized in Figure 2). However, ultimately with severe or 
prolonged activation, these mechanisms are deleterious to beta cell function and 
mass, resulting in T2D. Although it may be difficult to fully block each of these 
response pathways, a good therapeutic approach to prevent the loss of 
functional beta cell mass is to find commonalities in the destructive mechanisms 
of multiple stressors. Identifying points of convergence in signaling pathways 
may yield the most effective therapeutic targets for preventing or treating T2D at 
the level of the beta cell.  The following subsections will briefly review critical 
stressors implicated in the development of T2D and were the focus of my thesis 
work.  
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Figure 2.  
 
 
Figure 2. Summary of stressors in diabetes and the beta cell responses. 
Cytokines, adipokines, glucotoxicity, lipotoxicity, and glucocorticoid steroids are 
all stressors that lead to beta cell destruction. These stressors elicit beta cells to 
activate inflammatory stress, ER stress, and metabolic/oxidative stress 
responses in order to combat the deleterious effects. Chronic activation of these 
responses lead to a decline in functional beta cell mass and overt T2D. 
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CYTOKINES 
Inflammation is evident in many organs of diabetic patients and underlies 
part of the pathophysiology within the pancreatic islets as well as other tissues 
that participate in the long-term complications associated with poorly controlled 
diabetes. Serum samples of patients with diabetes and/or obesity are indicative 
of an inflammatory status as there are increased levels of circulating 
proinflammatory markers (Horvath et al. 2013, Donath and Shoelson 2011, 
Hatanaka et al. 2006, Spranger et al. 2003, Carstensen et al. 2010, Zhang, Xiao, 
et al. 2014). Additionally, adipose tissue of obese individuals have increased 
levels of activated T-cells and proinflammatory adipokines that contribute to the 
systemic inflammatory status. The inflammatory status of diabetes is also evident 
within the pancreatic islets as there are elevated levels of cytokine production by  
beta cells, along with increased CD68+ macrophage cells or other immune 
cells residing near beta cells. The beta cell-specific antigen(s) that activates the 
inflammatory response is still unknown. However, this event entails cytokines 
that activate the receptors from the Toll-like receptor (TLR) family (TLR2 and 4 in 
humans) to: 1) auto-stimulate further production of the master cytokine 
interleukin-1 beta (IL-1β) in an autocrine fashion; 2) recruit further immune cell 
infiltration by releasing other paracrine-acting chemokines and cytokines; 3) 
induce fibrosis and apoptosis; and 4) impair insulin production and secretion. 
Inflammatory cells recruited to the islet include T helper cells, cytotoxic T 
cells, macrophages, and dendritic cells. It is yet unknown as to which event 
occurs first; however, inflammatory cells in the islet cause death of beta cells, 
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thereby releasing antigens that trigger the recruitment of even more inflammatory 
cells to “clean up” and engulf islet debris. In either event, at low concentrations of 
inflammation, IL-1β will activate FLICE-inhibitory protein (FLIP), an inhibitor of the 
Fas signaling pathway, to induce beta cell proliferation and function in a nuclear 
factor kappa-light-chain enhancer of activated B cells (NF-κB)-dependent manner 
that acts through Pancreatic and duodenal homeobox 1 (Pdx1) (Maedler et al. 
2006, Schumann et al. 2007). NF-κB is ubiquitously present in cells and upon 
activation, this transcription factor stimulates expression of genes involved in T-
cell development, maturation, and proliferation in order to maintain the proper 
amount of inflammatory mediators to protect from any antigenic damage. On the 
contrary, prolonged activation of NF-κB transcriptional activity is deleterious to 
beta cells as it maintains a consistent abundance of proliferating inflammatory 
cells and activates inducible nitric oxide synthase expression in beta cells, 
thereby inducing nitric oxide and beta cell death (as described in more detail 
below). 
In addition to impairing insulin production and secretion in beta cells, 
cytokines activate death pathways that work through various mechanisms, 
including but not limited to the activation of apoptosis, the inflammasome and 
cytotoxicity, all of which impact functional beta cell mass (Padgett et al. 2013, 
Donath and Shoelson 2011). IL-1β, interferon-gamma (IFN-), and tumor 
necrosis factor-1 alpha (TNFα) are the most prevalent proinflammatory cytokines 
that are pathologically detrimental to beta cells. Elevated cytokines activate the 
stress kinase, c-Jun N-terminal kinase (JNK), NF-κB signaling, and Janus Kinase 
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(JAK)/Signal transducer and activator of transcription (STAT) pathway, while 
increasing nitric oxide production and reactive oxygen species (ROS) . JNK 
activates pro-apoptotic transcription factors, such as AP-1, c-Jun, c-Fos, Jun-D, 
and ATF-2 under proinflammatory cytokine exposure (Eckhoff et al. 2003). 
Similarily, the JAK/STAT pathway aids in the activation of pro-apoptotic genes 
(Heim 1999). Nitric oxide and other free radicals induce DNA damage, interfere 
with mitochondrial iron-sulfur containing enzymes such as aconitase of the 
tricarboxylic acid cycle, and lead to the increase of mediators from the 
cyclooxygenase pathways, such as prostaglandins, thromboxane A2, and 
prostacyclin (Salvemini et al. 1993, McDaniel et al. 1996). Interestingly, repair of 
nitric oxide-induced DNA damage in beta cells requires JNK, and thus JNK is 
paradoxically both protective and harmful, depending on the severity or length of 
activation (Hughes et al. 2009). Although there is some induction of apoptosis 
through JNK and nitric oxide, cytokines also lead to beta cell death by disrupting 
ATP homeostasis and inducing cytotoxicity and necrosis rather than by apoptosis 
(Collier et al. 2006, Steer et al. 2006).  
Additionally, increased cytokines are associated with decreasing cell 
survival responses or insulin signaling. For example, TNFα-stimulated adipocytes 
or cytokine-stimulated beta cells display decreased phosphorylation of insulin 
receptor substrate-1 (IRS-1) and IRS-2, which are downstream of insulin receptor 
activation (Gurevitch et al. 2010, Hotamisligil et al. 1996). Lastly, cytokines such 
as IL-1β and IL-12 impair GSIS, and when the IL-1 receptor antagonist is used as 
a treatment in a diabetic rat model, there is improved proinsulin to insulin 
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processing (Donath et al. 2009, Taylor-Fishwick et al. 2013). As mentioned 
above, the inhibitory actions of cytokines on insulin secretion are mediated by 
nitric oxide, as it targets aconitase from the Krebs cycle, thus decreasing ATP 
production that is necessary for depolarization of the plasma membrane and 
insulin secretion (Corbett et al. 1991, Welsh et al. 1991). Therefore, increased 
cytokines result in cell death, inhibition of proinsulin to insulin processing, and 
impaired GSIS, which overall contribute to the decline in functional beta cell 
mass. 
 
GLUCOCORTICOIDS 
Obese individuals have elevated levels of cortisol, a glucocorticoid steroid 
hormone that promotes an anti-inflammatory response upon activation of the 
glucocorticoid receptor (GR). Additionally, obese and insulin resistant individuals 
have increased expression of 11-hydroxysteroid dehydrogenase, the enzyme 
that converts cortisone to the active cortisol (Duplomb et al. 2004, Davani et al. 
2000). Further, stress elicits the release of glucocorticoids into the bloodstream 
to regulate the release of glucose during the fight or flight response. Specifically, 
glucocorticoids suppress the immune system, stimulate gluconeogenesis and 
glycogenolysis, and activate genes regulating fat, protein, and carbohydrate 
metabolism. Upon ligand binding to GR, it transcriptionally represses genes such 
as NF-κB to promote an anti-inflammatory response. Although glucocorticoids 
are utilized for their role as an anti-inflammatory agent, caution is rendered as 
steroids induce insulin resistance and diabetes (Lansang and Hustak 2011, 
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Ferris and Kahn 2012, Boumpas, Anastassiou, et al. 1991, Boumpas, 
Paliogianni, et al. 1991, Saksida et al. 2014). Administering corticosterone to 
C57BL/6J mice via the drinking water for 5 weeks induces glucose intolerance, 
impairs insulin sensitivity, and causes dyslipidemia (Fransson et al. 2013).  
In addition to the deleterious effects that glucocorticoids have on the entire 
metabolic state in vivo, glucocorticoids are also markedly detrimental to beta 
cells. For example, intracellular cytosolic calcium levels are disrupted in response 
to glucose when isolated rat beta cells are cultured in increasing doses of 
corticosterone (Koizumi and Yada 2008). Therefore, the calcium required for first- 
and second-phase insulin secretion is decreased and does not allow for 
adequate insulin release from the beta cell. Elevated GR activation via 
dexamethasone, a synthetic GR agonist, also suppresses GSIS by increasing 
degradation of glucose transporter type 2 (GLUT2), the primary transmembrane 
carrier of glucose into beta cells that is necessary to metabolize and sense 
glucose for stimulation of insulin secretion (Gremlich, Roduit, and Thorens 1997). 
Additionally, dexamethasone treatment of immortalized rat beta cells and rat 
islets resulted in activation of FOXO1 transcriptional activity and a FOXO1-
dependent inhibition of the expression of Pdx1, a transcription factor essential for 
the differentiation, function, and maintenance of beta cells (Zhang et al. 2009). 
Overall, glucocorticoids lead to a decline in beta cell function by disrupting GSIS 
and the maintenance of beta cells. 
Studies in islets using dexamethasone have shown that along with 
suppressing insulin secretion, chronic stimulation of the GR activates beta cell 
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apoptosis, primarily through intrinsic mechanisms (Gruver-Yates and Cidlowski 
2013, Gruver-Yates, Quinn, and Cidlowski 2014).  INS-1 cells (an insulin-
secreting rat beta cell line) treated with dexamethasone had increased 
transferase-mediated dUTP nick-end labeling (TUNEL)-staining, caspase-3 
activation, decreased levels of the anti-apoptotic protein Bcl-2, and increased 
pro-apoptotic Bad and Bim expression (Ranta et al. 2006, Gruver-Yates, Quinn, 
and Cidlowski 2014). Additionally, stress kinases are upregulated during 
dexamethasone treatment of beta cells. Both p38 mitogen-activated protein 
kinase (p38 MAPK) and c-Jun N-terminal kinase (JNK) are activated with 
dexamethasone treatment, and pharmacologically inhibiting p38 MAPK reduced 
dexamethasone-induced damage in beta cells (Fransson et al. 2014). 
Interestingly, treatment with a JNK inhibitor in conjuction with dexamethasone 
augmented DNA fragmentation and death of beta cells, suggesting that 
dexamethasone primarily induces damage through the p38 MAPK pathway, and 
not the JNK pathway.  
In addition to regulating stress kinase signaling, glucocorticoids also 
decrease the redox-regulating ability of beta cells. Dexamethasone upregulates 
the expression of thioredoxin interacting protein (TXNIP), and decreases the 
antioxidant thioredoxin protein (TRX1) (Reich et al. 2012). This effect was 
dependent on p38 MAPK and was reversed by the GR antagonist RU486. 
Overall, studies utilizing dexamethasone treatment of beta cells in vitro indicate 
that GR activation promotes apoptosis, thus translating into a decline in beta cell 
mass. 
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GLUCO(LIPO)TOXICITY 
 As mentioned previously, insulin is released into the circulation to 
stimulate glucose disposal by peripheral tissues. In addition, insulin signals 
adipose tissue to inhibit lipolysis and stimulate lipogenesis. However, in the 
insulin resistant stage (pre-diabetes or T2D), these signals are diminished, 
leading to an accumulation of circulating free fatty acids, and in combination with 
hyperglycemia, they synergistically act on beta cells to exacerbate death signals 
(also known as glucolipotoxicity) (Poitout and Robertson 2002, Robertson et al. 
2004).  
Long-term exposure to saturated free fatty acids (FFA), such as palmitate, 
is especially harmful to non-adipose tissues (like the beta cells) because it 
provokes apoptosis (Lupi et al. 2002). FFA can trigger apoptosis by inducing the 
production of ROS, and also directly disrupting the structure and integrity of the 
endoplasmic reticulum (ER). Both events then lead to ER stress (described in 
detail in section I.D.) and the release of ER calcium stores to trigger the intrinsic 
mitochondrial apoptotic pathway (Kharroubi et al. 2004).  Controversy exists as 
to whether the deleterious effects of a high lipid environment for beta cells are 
not as robust without the presence of high glucose. This is because the high 
glucose environment switches the oxidation status of fatty acids by shunting 
them towards esterification pathways, leading to the intracellular accumulation of 
FFA.  
Similar to lipotoxicity, high concentrations of glucose alone, or 
glucotoxicity, are also known to induce similar deleterious effects. For example, 
17 
 
glucotoxicity induces oxidative stress by elevating peroxide levels and other ROS 
in human islets (Robertson 2004). Additionally, glucotoxicity also results in 
apoptosis of beta cells. One postulated mechanism for this is that high glucose 
concentrations upregulate the production of IL-1β, which activates inflammatory 
pathways as mentioned previously and also induces the Fas receptor, a receptor 
that mediates the extrinsic apoptotic pathway (Maedler, Fontana, et al. 2002, 
Maedler, Sergeev, et al. 2002). Glucotoxicity-induced apoptosis requires the 
proapoptotic Bcl-2 homology domain 3 (BH3)-only proteins Bim and Puma, and 
presenting their absence, beta cells are protected from ROS (Wali et al. 2014). 
Overall, these mechanisms contribute to the decrease in beta cell mass, 
however, an emerging consequence of glucotoxicity is that it is a major cause of 
beta cell dedifferentiation (Weir, Aguayo-Mazzucato, and Bonner-Weir 2013). 
Aside from decreasing beta cell mass, glucotoxicity also impairs beta cell 
function and GSIS by inhibiting the expression and activity of protein kinase A, a 
downstream effector of cAMP signaling that potentiates GSIS (Kong et al. 2014). 
Similar to glucotoxicity, in vivo models of glucolipotoxicity, including high 
fat feeding in mice, show increased inflammatory and oxidative stress markers as 
well as activation of apoptotic pathways. Saturated free fatty acids bind to 
lipopolysaccharide (LPS) receptors, such as toll-like receptor-4 (TLR4) to activate 
the inflammatory response and increase IL-1β expression. The exact cellular 
mechanisms of glucolipotoxicity are still incompletely understood, however, it is 
evident that there is also activation of stress kinases such as JNK, and ER stress 
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markers such as phosphorylated eIF2α (p-eIF2α) and C/EBP homology protein 
(CHOP) (Martinez et al. 2008).  
In addition to activating death signals, glucolipotoxicity can interfere with 
metabolic processes and impair insulin secretion of beta cells (Somesh et al. 
2013). Within a week of high fat feeding in C57BL/6J mice (60% kcal from fat) 
GSIS, is impaired (Stamateris et al. 2013). One fact to note, however, is that at 
this stage, beta cell compensatory responses are still fully engaged, 
characterized by increased beta cell proliferation, and hence, increased beta cell 
mass. Similar to the effects of glucocorticoids, glucolipotoxicity after the 
compensatory stage decreases glucose uptake into beta cells by reducing 
GLUT2 expression and also impairs downstream calcium release required for 
insulin secretion (Somesh et al. 2013, Gremlich et al. 1997). Further, 
glucolipotoxicity disrupts glucose metabolism by reducing glucokinase and 
pyruvate carboxylase, two major enzymes that mediate the catabolism of glucose 
and fatty acid synthesis. As a result, cellular NADPH, GTP, and ATP production 
are all reduced, thereby disrupting the insulin secretion process. Additionally, 
there are less intermediates for fatty acid oxidation and an increase in fatty-acyl 
CoA accumulation to form triglycerides within beta cells – i.e., fatty acids 
accumulate. 
Altogether, glucotoxicity activates inflammatory responses, increases 
ROS, and interferes with metabolic signaling. Similarly, glucolipotoxicity also 
activates similar responses, while at the same time induces ER stress, and 
impairs metabolic processes and beta cell function. Thus, these processes 
19 
 
negatively impact functional beta cell mass and are of great interest for further 
investigation. 
 
I.D. Beta cell stress responses 
 In response to stress, multiple pathways are activated to repair any 
deleterious effects or are activated to signal the cell to die, depending on the 
severity of the stress. In this section, I will provide an overview of general death 
signals and cell stress/survival pathways, and then elaborate on other responses 
to a specific type of stress, including oxidative and ER stress. 
 
DEATH SIGNALS 
Prolonged or severe activation of cellular stress pathways leads to either 
apoptosis or necrosis in order to execute the death of the cell. Apoptosis is 
activated by two distinct, but converging, pathways—the extrinsic and/or intrinsic 
pathways (Figure 3). Regardless of the apoptotic pathway, this form of cell death 
consists of a series of events that are energy-dependent and that ultimately lead 
to ordered fragmented DNA and organized apoptotic bodies. The extrinsic 
pathway is stimulated by extracellular signals that activate the death receptor, 
releasing cleaved caspase-8 from the DISC compartment that leads to 
downstream caspase-3 cleavage and ultimately apoptosis, whereas the intrinsic 
pathway is activated by intracellular stress that increases pro-apoptotic Bax and 
Bak translocation the mitochondrial membrane. This Bax/Bak localization allows 
for pore formation and the release of cytochrome c from the mitochondria to form 
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the apoptosome, which activates the downstream caspase cascade and 
apoptosis. Anti-apoptotic proteins such as Bcl-2, Bcl-xL, or MCL, however, can 
also translocate to the mitochondrial membrane to inhibit this process by blocking 
pore formation/release of cytochrome c. 
Necrosis is the other mechanism by which cells undergo death. This form 
of death is characterized by bursting of the cell and does not activate a specific 
program. Therefore, it is difficult to detect and block necrosis in cells, and usually 
it is determined to be necrotic cell death if it does not undergo characteristics of 
apoptosis. Some stressors that activate alternative death pathways include 
cytokines and inflammatory stress. Necrosis is characterized by a loss of plasma 
membrane integrity, random DNA degradation, recruitment of immune cells that 
elicit inflammation, impairment in the bioenergetics of the cell (e.g., decreased 
cellular ATP), and initiation of tissue repair mechanisms (Zong and Thompson 
2006). 
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Figure 3.  
 
 
Figure 3. Extrinsic versus intrinsic apoptotic pathways. The extrinsic and 
intrinsic pathways are distinct mechanisms that converge at cleavage of caspase 
3 to activate an apoptotic response that involves DNA fragmentation, blebbing, 
and formation of apoptotic bodies. The extrinsic pathway is stimulated by an 
external ligand that activates Fas-activated death receptors on the plasma 
membrane of the cell. Whereas, the intrinsic pathway is stimulated by 
mechanisms within the cell such as cell stress, ultraviolet (UV) rays, or DNA 
damage. 
 
22 
 
CELL STRESS AND SURVIVAL PATHWAYS 
After the initiation of beta cell stress, survival pathways are activated to 
maintain cellular integrity, function, and viability. However, with severe or 
prolonged induction of stress pathways, these signals lead to detrimental effects. 
Interestingly, many stressors stimulate pathways that converge onto a few 
cellular signaling cascades that involve mitogen-activated protein kinase (MAPK), 
c-Jun N-terminal kinase (JNK), p38, and Akt. 
The MAPK (ERK) pathway regulates proliferation, cell division, and 
differentiation. In a site of injury, mitogens and growth factors are produced to 
repair and regenerate the damaged area. Mitogens or growth factors act as 
stimuli to activate receptor tyrosine kinases that then dimerize and 
autophosphorylate their catalytic domains. In doing so, SH3-domain containing 
adaptor proteins facilitate the activation of the membrane-bound GTPase, Ras 
that then activates effector proteins that signal a downstream kinase cascade 
that involves Raf kinase, MEK 1/2 and ERK 1/2. ERK 1/2 activation induces 
nuclear translocation of the activator protein (AP)-1 family of transcription factors 
that target pro-proliferative genes such as cyclins, growth factors, and cytokines. 
This response must be tempered as too much activation of this proliferative 
pathway may lead to overgrowth and cancer. 
Other types of MAPKs that are stimulated under stress are JNK and p38. 
One major difference, however, is that these MAPK proteins are activated 
directly by factors often deleterious to the cell, such as hyperosmosis, oxidative 
stress, UV radiation, or inflammatory cytokines. Additionally, p38 and/or JNK 
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pathways cross-talk with the Ras/Raf/MEK/ERK pathway and act on similar 
effectors that result in the reparative and proliferative downstream responses. 
However, p38 and JNK also induce pro-apoptotic proteins. For example, 
whereas JNK targets the transcription factor c-Jun to activate transcription of 
genes necessary for proliferation, differentiation, and inflammation, it also 
upregulates p53, a tumor suppressor and stimulator of apoptosis. Likewise, p38 
upregulates pro-apoptotic proteins as well, and it is difficult to distinguish 
separate effector proteins between the two and depends on the cell context. 
Overall, their pathways have been shown to regulate apoptosis, inflammation, 
growth or cell cycle arrest, cell differentiation, and survival. 
One important survival pathway that is activated in beta cells is through 
insulin signaling, where Akt is the major hub of this pathway. Specifically, insulin 
binds to the insulin receptor, inducing a confirmational change leading to trans-
autophosphorylation of tyrosines on the other member of the homodimer and 
then recruitment of insulin receptor substrate-1 (IRS-1). Phosphorylation/ 
activation of IRS-1 at its serine 636 site activates phosphoinositide-3-kinase (PI3-
K) that subsequently allows for the formation of the second messenger, 
phosphatidylinositol (3,4,5) trisphosphate (PIP3) which is incorporated into the 
plasma membrane. PIP3 then forms a complex with Akt where it is 
phorsphorylated and activated by a phosphoinositide dependent kinase (PDK).  
Akt then controls cell survival by acting on a number of targets: (1) it binds to Bax 
and hinders its ability to translocate to the mitochondrial membrane, (2) it 
activates the mTOR pathway that is responsible activating the translation factor 
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S6 kinase to initiate ribosomal translation of mRNA, and (3) it phosphorylates 
and inhibits forkhead box-O1 (FOXO1), a transcription factor that inhibits 
proliferation. 
Overall, these pathways are important cell signaling events that determine 
the survival of the cell and have been extensively investigated in the field of islet 
biology in hopes of identifying methods to increase functional beta cell mass. For 
example, a transgenic mouse model with a constitutively active form of Akt was 
constructed and found to exhibit increased beta cell proliferation and overall beta 
cell mass (Fatrai et al. 2006). These pathways have been proven to be of 
importance within the beta cell and warrant further investigation. 
 
OXIDATIVE STRESS RESPONSE 
Reactive oxygen species (ROS) consist of multiple oxygen-containing 
radicals that are involved in cell signaling and homeostasis, for example with 
gene transcription and signaling for host defense mechanisms. ROS are 
produced by normal cellular metabolism with intermediates that include hydroxyl 
radical, superoxide radical, or hydrogen peroxide. Chronic accumulation of ROS 
causes oxidative stress in the islet. Furthermore, diabetic patients and obese 
patients with diabetes both display reductions in synthesis of glutathione, serum-
levels of glutathione peroxidase enzyme and its activity (Sekhar, McKay, et al. 
2011, Sekhar, Patel, et al. 2011, Goyal, Singhai, and Faizy 2011). Glutathione is 
an important anti-oxidant that prevents free radical-induced damage to cellular 
components. When overexpressed, glutathione peroxidase enzyme protects from 
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detrimental effects by high ribose concentrations on insulin transcription and 
insulin secretion (Robertson et al. 2007, Robertson and Harmon 2007). 
Normally, beta cells express relatively low levels of anti-oxidant enzymes 
(Robertson et al. 2003). Although glutathione peroxidase enzyme is absent in 
islets, manganese superoxide dismutase-1 and -2 (SOD-1 and SOD-2) are the 
major forms of anti-oxidants that are detected in rodent and human islets (Kang 
et al. 2014). Without SOD2, high fat-fed mice that have increased oxidative 
stress, impaired GSIS, but intact insulin sensitivity. Therefore, the increase in 
oxidative stress within beta cells, in combination with less anti-oxidant capability, 
directly results in a worsening of beta cell health and the decline in both function 
and mass, independent of insulin resistance. 
 
ER STRESS RESPONSE 
The ER is a cellular organelle responsible for calcium storage and protein 
folding. However, when these processes go awry, such as during the high 
secretory demand of beta cells in the pre-diabetic state, the ER is subjected to 
stress and multiple adaptive pathways are stimulated in the unfolded protein 
response (UPR). The UPR is separated into three arms mediated by inositol-
requiring enzyme-1α (IRE1α), activating transcription factor-6 (ATF6), or protein 
kinase RNA-like ER kinase (PERK). Each of these transducers sense stress in 
the ER (e.g., increased unfolded or misfolded proteins or inefficient capacity to 
fold proteins properly) and together facilitate a reduction in protein load, increase 
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the capacity of the ER to manage the high demand, and trigger cell death if the 
stress is persistent and unresolved (Hotamisligil 2010).  
As briefly mentioned above, the canonical pathway for the UPR arms 
include: 1) PKR-like endoplasmic reticulum kinase (or PERK) phosphorylates 
eukaryotic initiation factor 2α, that then upregulates the transcription factors 
ATF4 and CHOP. Overall, this arm works to suppress general protein translation 
(Shi et al. 1998); 2) IRE1α activation leads to recruitment of several signaling 
molecules that can engage survival-related signals, and it’s an enzyme with 
endoribonuclease activity that splices cytoplasmic mRNA, including that for X 
box–binding protein 1 (Xbp-1), producing the spliced Xbp1-s mRNA that 
produces an active transcription factor for upregulation of UPR chaperone genes 
and components of the ER-Associated degradation pathway (Hetz et al. 2011, 
Lee et al. 2011, Tirasophon, Welihinda, and Kaufman 1998, Wang et al. 1998); 
3) Lastly, ATF6 translocates from the ER to the Golgi apparatus, where it is 
processed by proteases to become an active transcription factor that aids in 
producing more chaperones to increase the folding capacity of the ER to resolve 
the misfolded protein issue (Haze et al. 1999, Engin et al. 2014). 
Under chronic or severe UPR activation and ER stress, the intrinsic 
apoptotic pathway and death signals are initiated in beta cells. For example, both 
ATF6 and PERK increase ATF4 and the transcription factors CHOP and p53 
(Hetz et al. 2011). These transcription factors then downregulate Bcl-2 
expression, an anti-apoptotic mitochondrial BH3-domain protein, while at the 
same time upregulate the pro-apoptotic mitochondrial proteins Bax and Bak, 
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which, as mentioned previously, form a pore on the mitochondrial membrane to 
release cytochrome c and ultimately induce apoptosis (McCullough et al. 2001, 
Puthalakath et al. 2007, Galehdar et al. 2010). Additionally, the IRE1 arm of the 
UPR leads to phosphorylation of ASK1 that then activates JNK, which may also 
promote Bax/Bak pore formation and apoptosis (Mauro et al. 2006, Hetz et al. 
2011). In other words multiple signaling cascades feed into the ER stress-
mediated apoptotic program.   
Although the events leading to apoptosis are not fully understood, CHOP 
and phosphorylated JNK are the downstream mediators of the UPR implicated to 
activate apoptosis through transcriptional upregulation of pro-apoptotic BH3-
domain proteins, such as Bim, PUMA, and NOXA and the promotion of Bax/Bak 
pore complex formation on the mitochondrial membrane (Back et al. , Hetz et al. 
2011, Puthalakath et al. 2007). Under such circumstances, apoptosis is triggered 
by the subsequent release of cytochrome c, which along with caspase 9 and 
Apaf-1 form the apoptosome, thereby activating executioner caspases such as 
caspase 3 and 7 (Dahmer 2005).  
Aside from initiating the apoptotic pathway, prolonged ER stress inhibits 
Akt cell survival signaling (Chien-Hung Chen 2011). Recent evidence established 
that constitutively active Akt inhibits thapsigargin- and tunicamycin-induced 
phosphorylation of JNK that subsequently leads to less caspase-3 cleavage and 
death. One proposed mechanism by which this occurs is through activation of 
phosphatases that directly dephosphorylates Akt to inactivate cell survival 
signaling.  
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Pancreatic islets of patients with T2D display increased markers of ER 
stress, including phosphorylated eIF2α and CHOP (Laybutt et al. 2007, Kim, Xu, 
and Reed 2008, Huang et al. 2007). Furthermore, diabetic obese db/db mice 
display increased phosphorylated eIF2α, IRE1α, and Xbp-1 processing. High fat 
diet and glucolipotoxicity induce ER stress in vivo and in vitro, respectively, and 
are currently used as T2D models to examine molecular pathways involved in 
beta cell death. Free fatty acids evoke the UPR by incompletely understood 
mechanisms, but ultimately lead to beta cell apoptosis (Tabas and Ron 2011, 
Ron and Walter 2007).  Therefore, it is necessary to understand the ER stress 
mechanisms in these models of T2D and how p21 is involved in this process. 
 
I.E. Cell cycle regulation during stress 
The cell cycle machinery regulates proliferation and is composed of 
cyclins that directly interact with cyclin-dependent kinases (CDKs) to allow 
progression past each cell cycle checkpoint when activated by phosphorylation. 
CDKs phosphorylate substrates necessary for preparation of the cell to undergo 
DNA replication and cell mitosis. On the other hand, cell cycle inhibitors (CIPs) 
bind to and inactivate CDK-cyclin complexes and are divided into two families – 
the CIP/KIP and INK4 subfamilies (Fuster et al. 2010). The INK4 family of 
inhibitors (p15, p16, p18, p19) primarily regulates the G1 to S phase transition, 
whereas the CIP/KIPs (p21, p27, and p57) are capable of regulating entry into 
each of the phases, G1, S, G2, and mitosis.  
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The cell cycle machinery is tightly controled under stress conditions in the 
beta cell. In doing so, there is a mechanism to halt proliferation of damaged cells 
to allow enough time for repair mechanisms to take place.  This process is 
engaged in order to prevent damaged and dysfunctional beta cells from 
replicating, thereby preventing the propagation of dysfunctional cells, which, if not 
restrained, could release aberrant proteins that could serve as auto-antigens. 
Expression of the cell cycle regulators is dynamically regulated during a 
variety of beta cell stresses. For example, upon exposure of beta cells to a high 
glucose environment, there is an initial stage of proliferation induced and 
attributed to an increase in cyclins D1 and B1 (Hsu et al. 2009). However, with 
chronic high glucose, p21 protein levels are induced, suggesting it is activated in 
response to a chronic stress within the beta cell, presumably to inhibit 
proliferation (Zhang, Li, et al. 2014). In contrast, exposure to high lipids inhibits 
glucose-induced proliferation by inducing the cell cycle inhibitors p16 and p18 
(Pascoe et al. 2012).  Similarly, high circulating fatty acids upregulate the 
expression of p16 and p18. Furthermore, knockdown of p16 and p18 restores 
glucose-induced proliferation in beta cells. A later study by this group also 
determined that within one week of high fat feeding in mice, islets had increased 
BrdU-positive proliferating cells, while at the same time elevated levels of cyclins 
D2 and A2. These studies are examples showing that cell cycle regulators are 
modulated under various stress conditions. 
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I.F. p21 and its regulation of functional beta cell mass 
p21 is one of the cell cycle inhibitors that is elevated in diabetic models. 
For example, hyperglycemic Zucker diabetic fatty rats and ob/ob mice display 
increased p21 expression in islets (Kaneto, Kajimoto, Fujitani, et al. 1999, 
Kaneto, Kajimoto, Miyagawa, et al. 1999, Keller et al. 2008). Interestingly, 
pancreatic beta cells of patients with T2D exhibit lower DNA methylation of the 
p21 gene, and thus higher p21 gene expression (Marselli et al. 2010, Taneera et 
al. 2013, Dayeh et al. 2014). These data support the idea that p21 regulates 
functional beta cell mass during stressful environments of the diabetic milieu. It is 
possible that the increased p21 expression under diabetic conditions contributes 
to negative regulation on both beta cell mass and beta cell function. 
p21 is a CIP that is upregulated during DNA damage and cell stress 
through both p53-dependent and -independent mechanisms (Russo et al. 1995, 
Gudas et al. 1995, Michieli et al. 1994, el-Deiry et al. 1994). Findings in my thesis 
and by others demonstrate that p21 is increased under conditions of 
endoplasmic reticulum (ER) stress and impairs proliferation (Yamada et al. 
2006). p21 halts proliferation at the G1/S transitions by binding to the CDK4/6-
Cyclin D and CDK2-Cyclin E complexes. In addition, p21 blocks the G2/M 
checkpoint by binding to the CDK1-Cyclin B complex. Further functions of p21 
include binding to and inhibiting proliferating cell nuclear antigen, which is 
required for DNA polymerase activity (Soria et al. 2008). In fact, p21 knockout 
mice were examined to determine whether islet hyperplasia could be observed, 
and to further enhance beta cell proliferation during mitogen-induced beta cell 
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mass expansion by placental lactogen (Cozar-Castellano, Weinstock, et al. 
2006). However, their findings concluded that p21 did not influence any of these 
factors, and compensation by other cell cycle inhibitors could be the reason for 
the fact that p21 alone is not essential for maintaining beta cell cycle arrest. 
Although the role for p21 during stress has been primarily implicated to 
halt proliferation for cell repair, some evidence suggests that it is involved in the 
death process. Transgenic mice with beta-cell specific p21 overexpression in 
adulthood displayed hyperglycemia and increased apoptotic cells over time 
(Yang et al. 2009). Furthermore, human islet amyloid polypeptide (IAPP), a 
hormone co-secreted with insulin, acts as another stressor of beta cells and 
induces p21 expression and apoptosis (Zhang et al. 1999, Zhang, Fujita, and 
Tsuruo 1999). Lastly, both oxidative stress and chronic elevated glucose also 
induce p21 expression (Zhang, Li, et al. 2014, Kaneto, Kajimoto, Fujitani, et al. 
1999). The mechanisms by which p21 induces death are still unclear, however, 
beta cells that have suppressed expression of protein kinase C (PKC)-delta have 
elevated levels of p21 and increased TUNEL+-stained apoptotic cells (Ranta et 
al. 2011). This suggests that PKC-delta is potentially a way that p21 expression 
is regulated to induce death. Taken together, p21 is induced by beta cell 
stressors that lead to a decline in beta cell mass. 
Aside from regulating processes that affect beta cell mass, p21 has also 
been implicated in regulating beta cell function. For example, direct oxidative 
stress by peroxide, or rat islets with impaired anti-oxidant defenses, exhibit 
elevated p21 expression that is implicated in the decline of beta cell dysfunction 
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as it decreases insulin gene transcription when overexpressed in isolated rat 
islets (Kaneto, Kajimoto, Fujitani, et al. 1999, Tarry-Adkins et al. 2009). Recent 
findings also show that p21 overexpression in beta cells impaired GSIS, and 
interestingly increased glucagon secretion from alpha cells (Dayeh et al. 2014). 
Glucagon negatively regulates beta cell’s function of secreting insulin, therefore, 
this is another way in which p21 regulates beta cell function. However, it is yet to 
be determined whether p21 induction is evident in all cell types of islets from 
diabetic donors, or whether its expression regulation is specific to the beta cell.  
Findings from the body of work mentioned above indicate that p21 is also 
transcriptionally upregulated during ER stress, and implicate p21 itself as a pro-
apoptotic stimulator in beta cells. However, the molecular events by which p21 
induces apoptosis are unknown and further explored in this thesis project. In 
doing so, it will provide insight to the influence of p21 on functional beta cell mass 
during the progression to T2D.  
 
I.G. Thesis Hypothesis & Specific Aims 
The overall objective of this thesis project was to determine a common 
factor between multiple beta cell stressors that is detrimental to functional beta 
cell mass. Theoretically, by inhibiting or therapeutically targeting this common 
factor, we will preserve or restore functional beta cell mass. As mentioned 
previously, cell cycle regulators are involved during a variety of forms of beta cell 
stress and were examined in this thesis project. Because p21 is upregulated 
during DNA damage and stress in other cell types, I hypothesized that p21 will 
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antagonize functional beta cell mass during beta cell stress. The specific aims for 
this project were to: (1) determine how beta cell stressors modulate cell cycle 
regulators and examine p21’s role in cell death, and (2) determine the 
contribution of p21 to ER stress-mediated beta cell apoptosis and the molecular 
events that trigger this process after glucolipotoxicity stress. 
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Chapter II. Materials and Methods 
 
II.A. Cell culture and rodent islet isolation 
832/13 and 828/33 cell lines, derived from the parental rat insulinoma cell 
line, INS-1, were maintained in complete RPMI 1640 medium with (L)-glutamine 
and 11.2 mM glucose supplemented with 50 units/ml penicillin, 50 µg/ml 
streptomycin, 10 mM HEPES buffer, 10% fetal bovine serum (FBS) and INS-1 
supplement as described previously (Hohmeier et al. 2000, Tran et al. 2003). 
Both of these clonal cell lines have been engineered to stably express human 
insulin under the control of the cytomegalovirus (CMV) promoter and thus have 
robust insulin content and GSIS (due to clonal selection); the 828/33 cells also 
stably overexpress Bcl-2.  Hepatocellular carcinoma HepG2 cells were 
maintained in DMEM containing 4.5 g/L (D)-glucose, 2 mM (L)-glutamine, 50 
units/ml penicillin, 50 µg/ml streptomycin, 1 mM sodium pyruvate, and 10% FBS. 
Pancreatic islets were isolated from male Wistar rats weighing 200-250 g, 
C57BL6 wild-type mice at 8-10 weeks of age, and F2 hybrid B6129SF2/J wild-
type and p21-knockout (B6.129S2-cdkn1; #003263) mice at 8-10 weeks of age 
(from Jackson Laboratory) using a protocol approved by the Indiana University 
School of Medicine Institutional Animal Care and Use Committee (Li et al. 2009). 
Islets were cultured in RPMI medium with (L)-glutamine and supplemented with 8 
mM glucose, 10% FBS, 50 units/ml penicillin, and 50 µg/ml streptomycin. 
Freshly-isolated islets were hand-picked into separate treatment groups and 
placed in the treatment media on the same day of isolation.  
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II.B. Drug treatment groups and adenoviral transduction 
Beta cell lines were treated with complete medium containing the synthetic 
glucocorticoid dexamethasone (100 nM for 16 h, BioVision, Mountain View, CA) 
or the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor thapsigargin 
(1 µM for 6 h, Sigma, St. Louis, MO) and compared to DMSO (Sigma) as a 
control. Isolated primary islets were treated with 100 µM dexamethasone or 1 
mM thapsigargin for either 24h (rat islets) or 48h (mouse islets) in complete 
RPMI medium.  Dose- and time-dependent experiments were also performed 
with thapsigargin treatment.  For dose-dependent experiments, 832/13 cells were 
treated with DMSO or 250, 500, or 1000 nM for 6 h.  For time-dependent 
experiments, 832/13 cells were treated with DMSO or 1000 nM thapsigargin for 
0.5, 1, 2, 4, or 6 h.  At the end of the experiments, cells were harvested for 
collection of either mRNA for either quantitative real-time PCR or protein for 
immunoblotting. 
For cytokine experiments, beta cell lines were treated with complete 
medium containing 10 ng/mL recombinant rat IL-1β and 100 U/mL recombinant 
rat IFNγ (Prospec, Brunswick, NJ) that were each reconstituted in 0.1% BSA 
made in water. Cells were treated with the combination of both cytokines for 
either 6 or 24 h and later underwent cytoxicity and viability assays to measure 
nitric oxide production or the nitrate/nitrate ratio using the Griess assay (Promega 
G2930). 
Beta cell lines were treated with complete medium containing BSA vehicle 
or BSA-conjugated palmitate (400 M for 2, 4, 6, or 8 h) as previously described 
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(Chen et al. 2010) in either 5 mM glucose- or 20 mM glucose-containing 
complete medium. In short, BSA-conjugated palmitate was prepared by 
dissolving sodium palmitate (Sigma, St. Louis, MO) in a 1:1 ethanol/water 
solution for 10 min at 65°C making a final stock concentration of 150 mmol/l. The 
control BSA vehicle was prepared with the 1:1 ethanol/water solution mixed with 
BSA (10% in water, Sigma, St. Louis, MO). The stock palmitate solution was then 
complexed with BSA (10% in water) at a 5:1 fatty acid/BSA ratio by incubating it 
for 1h at 37°C. BSA-conjugated palmitate and the vehicle-BSA solutions were 
aliquoted and frozen in -20°C until ready to treat cells. These aliquots only 
underwent a maximum of three freeze-thaw cycles. 
For gene overexpression, 832/13 cells were transduced for 48 h with 
purified adenoviruses expressing green fluorescent protein under the control of 
the CMV promoter (AdCMV-GFP), human p21 under control of the CMV 
promoter (AdCMV-p21, Vector Biolabs), or human Bcl-2 under the control of the 
CMV promoter (AdCMV-Bcl2, kind gift from Dr. Curiel at Washington University  
(Bilbao, Contreras, Eckhoff, et al. 1999, Bilbao, Contreras, Gomez-Navarro, et al. 
1999, Bilbao, Contreras, Mikheeva, et al. 1999) with 200 multiplicities of infection. 
The exception to this time frame was when using purified adenovirus expressing 
human dominant negative c-jun N-terminal kinase (JNK1; Seven Hills 
Bioreagents, Cincinnati, OH) under control of the CMV promoter. In this case, 
832/13 cells were transduced for 16 h and treated with 1 M thapsigargin for the 
last 6 h of the transduction period. Rat islets were transduced immediately 
following isolation for 72 h with 1000 multiplicities of infection (assuming an islet 
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contains 1000 cells). Cells and islets were cultured in adenoviral-containing 
media only for the first 24 h and subsequently switched into fresh medium for the 
remainder of the experiment before harvesting. 
The pharmacological inhibitors for JNK and p38, 10 M SP600125 and 10 
M PD169316 (Sigma, St. Louis, MO), respectively, were replenished in 
complete media every 8 h during the 48 h transduction period with adenovirus. In 
other words, adenovirus-containing media with fresh drug replaced the older 
media every 8 h for the first 24 h. The second 24 h consisted of replacing older 
media with adenovirus-free media with fresh drug every 8 h. Control treatment 
was DMSO for these experiments. 
 
II.C. [3H]-Thymidine incorporation 
Proliferation was assessed via [3H] methyl-thymidine incorporation into 
genomic DNA by incubating 832/13 cells or isolated rat islets in 1 µCi/ml for 4 or 
16 h, respectively. Islets that underwent drug treatments or adenovirus 
transduction were separated into triplicate groups of 30 as previously described 
(Fueger et al. 2012). Cold 10% trichloroacetic acid was used to precipitate DNA 
from each sample, and subsequently solubilized with 0.3 N NaOH. The total 
amount of [3H]-thymidine incorporation was measured using liquid scintillation 
counting and normalized to cellular protein content. 
 
 
 
38 
 
II.D. Quantitative real-time polymerase chain reaction  
To isolate RNA, 832/13 cells and approximately 50 isolated rat islets were 
lysed in RLT buffer containing 1% β-mercaptoethanol and harvested using the 
RNeasy mini or micro kit, respectively (QIAGEN, Valencia, CA). Next, cDNA was 
synthesized using the High Capacity Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA). Samples underwent real-time PCR using Taqman 
Gene Expression Master Mix Reagents and Gene Expression assay probes 
(Table 1; Applied Biosystems), except for transcript analysis of Xbp1-s where a 
FAM-labeled probe for Xbp1-s was made using the following sequence:  
5’-GGCCCAGTTGTCACCTCCCC-3’. The forward and reverse primers used 
contained the sequences 5’-CTGAGTCCGCAGCAGGT-3’ and  
5’-TGTCAGAATCCATGGGAAGA-3’, respectively. The reaction for this 
sequence consisted of 1 M FAM labeled probe, 2X Taqman Master mix, 2.5X 
cDNA, and 4 M of each primer. The threshold cycle (CT) method (Livak and 
Schmittgen 2001) was used to calculate relative quantities of mRNA products; 
each sample was performed in triplicate and normalized by the CT value of 
GAPDH, an internal control within each reading. 
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Table 1.  List of Taqman assays used. 
Name Catalog # Probe label 
Mouse CHOP Mm01135937_g1 FAM 
Mouse GAPDH 4352339E-1208041 VIC 
Mouse p21 Mm00432448_m1 FAM 
Human GAPDH Hs02758991_g1 VIC 
Human p21 HS00355782_m1 FAM 
Rat GAPDH 4352338E-1211016 VIC 
Rat CHOP Rn01450526_m1 FAM 
Rat p21 Rn00589996_m1 FAM 
Rat Bim Rn00674175_m1 FAM 
Rat p16 Rn01433231_m1 FAM 
Rat p16 Rn00580664_m1 FAM 
Rat p18 Rn00590868_m1 FAM 
Rat p19 Rn00486943_m1 FAM 
Rat p27 Rn00582195_m1 FAM 
Rat p57 Rn00711097_m1 FAM 
Rat Bcl-2 Rn99999125_m1 FAM 
Rat Bax Rn02532082_g1 FAM 
Rat Bak Rn00587491_m1 FAM 
Rat Bad Rn00575519_m1 FAM 
Rat Bclx-L Rn00437783_m1 FAM 
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II.E. Flow cytometry  
After adenoviral transduction, the media from cultured 832/13 cells were 
collected and spun at 1900 rpm at 4ºC for 3 min in clear polyethylene tubes. 
Cultured cells were then washed with PBS and trypsinized until cells detached 
from the plate. Cells were gently collected and spun together with the apoptotic 
cells (i.e., those collected from the media) at 1000 rpm for 3 min at 4ºC. 
Supernatants were removed and cells were washed with PBS, vortexed, and 
spun at 1900 rpm for 10 min at 4ºC. Duplicate samples were either processed for 
cell cycle or apoptosis analysis. For cell cycle analysis, samples were 
resuspended and stained with propidium iodide using the Guava cell cycle 
reagent (Millipore, Billerica, MA). For apoptosis analysis, samples were 
resuspended and co-stained with Annexin V-APC (Invitrogen, Carlsbad, CA) and 
propidium iodide (BioVision) in annexin-binding buffer (BioVision). Cells were 
sorted on a BD FACSCalibur APC instrument using the CellQuest Pro software 
(BD Biosciences, San Jose, CA). Cell cycle populations were analyzed with the 
ModFit LT Application. 
 
II.F. Immunoblot analysis  
Cells or approximately 150 isolated islets were washed and lysed with 
radioimmunoprecipitation buffer (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA) supplemented with protease inhibitors (Santa Cruz Biotechnology, Inc) and 
phosphatase inhibitor cocktails 2 and 3 (Sigma). Total cellular protein content 
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was quantified using the BCA assay kit (Pierce, Rockford, IL). Protein samples 
(30 µg) were heated with NuPage reducing agent and resolved on NuPage 10% 
Tris-Bis gels (Invitrogen). Proteins were transferred onto Immobulin-FL 
membranes (Millipore) and membranes were incubated overnight at 4ºC with 
primary antibodies (see Table 2) that were diluted in polyvinylpyrrolidone (PVP) 
(Sigma) (Haycock 1993) or Signal Enhancer HIKARI 250 (SE) (Nacalai USA). 
The loading control for all immunoblots was actin. Primary antibodies were 
detected by incubating membranes with IRDye 700- or 800-conjugated 
secondary antibodies for 1 h; fluorophore-labeled protein bands were detected 
on the Odyssey System (LI-COR, Lincoln, NE) and were quantified using ImageJ 
software (National Institutes of Health, Bethesda, MD). 
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Table 2. List of primary antibodies. 
Antibodies Dilution Catalog # Company 
Actin 1:5000 PVP 691001 MP Biomedical 
Akt 1:1000 SE 2920S Cell Signaling 
Bak  1:1000 SE 06-536 Millipore 
Bax  1:1000 PVP 06-499 Millipore 
Bcl-2 1:1000 SE sc-7382 Santa Cruz 
Bim  1:1000 PVP 2933P Cell Signaling 
Caspase 3 1:1000 PVP 9662S Cell Signaling 
Caspase 8 1:1000 PVP 9746S Cell Signaling 
c-Jun  1:1000 SE 9165S Cell Signaling 
eIF2  1:1000 PVP 2103S Cell Signaling 
FOXO1  1:1000 SE 2880S Cell Signaling 
IRS-1  1:1000 SE 51-9002004 BD Transduction Lab 
JNK  1:1000 PVP 9252S Cell Signaling 
p21 1:200 PVP sc-397 Santa Cruz 
phospho-Akt [T308] 1:1000 SE 4056S Cell Signaling 
phospho-cdk1 [pTpY14/15] 1:1000 SE 44-686G Biosource 
phospho-c-Jun 1:1000 SE 9164S Cell Signaling 
phospho-eIF2 1:1000 SE 3398S Cell Signaling 
phospho-FOXO1  1:1000 SE 9461S Cell Signaling 
phospho-IRS-1 1:1000 SE 2388 Cell Signaling 
phospho-JNK 1:1000 PVP 9251S Cell Signaling 
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II.G.  siRNA transfection  
For siRNA-mediated suppression of Bax and Bak, preannealed siRNA 
duplexes from Ambion (ID # 49750 and 190465, respectively) were utilized and 
compared to a scrambled control siRNA as previously described (Collier et al. 
2006). 832/13 cells were incubated for 24 h with complete medium containing a 
final concentration of 0.1 µM siRNA in Dharmafect transfection reagents 
(ThermoScientific, Waltham, MA). Subsequently, adenovirus transduction 
occurred for the remaining 48 h of culture before harvesting for protein and 
mRNA analysis. 
Stealth siRNA technology was utilized to suppress Bim expression (Life 
Technologies). Stealth control (Life Technologies) was used as a negative 
control that did not affect basal Bim expression. The custom stealth RNA 
sequence used for Bim was 5’-CGAGGAGGGCGUUUGCAAACGAUUA-3’ and 
was used at a final concentration of 50 nM using Lipofectamine 2000 (Life 
Technologies) as the transfection reagent in Optim-MEM Reduced Serum 
Medium (Life Technologies). 
 
II.H. Glucose-stimulated insulin secretion 
832/13 and 828/33 cells underwent static incubation GSIS after 
transduction with adenovirus for about 45 h. The cells were plated on two 12-well 
plates designated for low glucose or high glucose incubation and were at 100% 
confluent before starting the procedure. Cells were pre-incubated for 1 h in 2.5 
mM glucose-containing buffer consisting of 10X secretion assay buffer (1.14 M 
44 
 
NaCl, 47 mM KCl, 12 mM KH2PO4, 11.6 mM MgSO4), 1M HEPES, 0.25 M CaCl2, 
35% BSA (0.2%), NaHCO3 (25.5 mM) in water. Cells were then switched to 
either 2.5 mM glucose (basal) or 15 mM (stimulatory) glucose-containing buffer 
for 1 h. Media of each sample (in triplicate) was used in an insulin 
radioimmunoassay with the insulin Coat-a-Count kit (Siemens Healthcare). 
 
II.I. Cell death assay 
Islets were isolated from wild-type or p21-knockout mice and on the same 
day treated with DMSO or 10 M thapsigargin in 8 mM glucose RPMI complete 
media for 48 h. 40 islets were used in the Cell Death Detection ELISA PLUS 
assay (Roche Diagnostics). In short, islets were washed, lysed, and 20 l lysate 
(in duplicate) was incubated with 1:1 anti-histone-biotin/anti-DNA-peroxidase 
immunoreagent on streptavidin-coated microplate wells for 2 h. As a positive 
control, DNA-histone-complex was incubated (in duplicate) in extra wells. After a 
few washes, a colorimetric substrate was incubated for 5-10 min and measured 
using a spectrophotometer. Enrichment of histone-associated-DNA nucleosomal 
fragments in the cytoplasm was then calculated for each read and duplicates 
were then averaged to give a single value per treatment group. Readings from 
each mouse were then normalized to its own DMSO control to calculate the fold-
induction of nucleosome enrichment with thapsigargin. 
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II.J. Statistical methods  
For analysis between two groups, Student’s t-test was used, and 
differences were considered significant when p < 0.05. Comparisons between 
GFP- and p21-overexpressing groups in the cell lines were performed using a 
two-tailed Student’s t-test; islet experiments were analyzed using a paired two-
tailed t-test. One-way analysis of variance (ANOVA) was used in experiments 
that had three or more groups.  Differences within ANOVA were determined 
using Tukey’s post-hoc tests with significance determined when p < 0.05.  All 
data are reported as means ± SEM. 
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Chapter III. Stress-Induced Upregulation of p21 Activates Apoptosis in 
Pancreatic Beta Cells. 
 
III.A.  Synopsis 
Diabetes manifests from a loss in functional beta cell mass, which is 
regulated by a dynamic balance of various cellular processes including beta cell 
growth, proliferation, and death as well as secretory function. The cell cycle 
machinery comprised of cyclins, kinases, and inhibitors regulate proliferation. 
However, their involvement during beta cell stress during the development of 
diabetes is not well understood. Interestingly, in a screen of multiple cell cycle 
inhibitors, p21 was dramatically upregulated in INS-1-derived 832/13 cells and 
rodent islets by two pharmacologic inducers of beta cell stress, dexamethasone 
and thapsigargin. We hypothesized that beta cell stress upregulates p21 to 
activate the apoptotic pathway and suppress cell survival signaling. To this end, 
p21 was adenovirally overexpressed in pancreatic rat islets and 832/13 cells. As 
expected, p21 overexpression resulted in decreased [3H]-thymidine 
incorporation. Flow cytometry analysis in p21-transduced 832/13 cells verified 
lower replication as indicated by a decreased cell population in S-phase and a 
block in G2/M transition. The sub-G0 cell population was higher with p21 
overexpression and was attributable to apoptosis, demonstrated by increased 
annexin-positive stained cells and cleaved caspase 3 protein. p21-mediated 
caspase 3 cleavage was inhibited by either overexpression of the anti-apoptotic 
mitochondrial protein Bcl-2 or siRNA-mediated suppression of the pro-apoptotic 
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proteins Bax and Bak. Therefore, an intact intrinsic apoptotic pathway is central 
for p21-mediated cell death. In summary, our findings indicate that beta cell 
apoptosis can be triggered by p21 during stress, thus being a potential target to 
inhibit for protection of functional beta cell mass. 
 
III.B. Introduction 
Diabetes is a metabolic disease characterized by a decline in functional 
beta cell mass that is attributed to either impaired insulin secretion, or an 
imbalance in the proliferation to death ratio of beta cells.  In the adult pancreas, 
beta cell proliferation in islets is minuscule (Butler et al. 2003, Cozar-Castellano, 
Fiaschi-Taesch, et al. 2006, Kassem et al. 2000, Teta et al. 2005). However, in 
diseased states there could be a decrease in the already low rate of proliferation 
in addition to an increase in death of existing beta cells. Progress towards 
understanding the events that lead to beta cell death or inhibition of proliferative 
potential are necessary to identify novel therapeutic targets for diabetes. 
Specifically, mechanisms to inhibit cell death and release the inhibition on 
proliferation are essential to protect and/or restore functional beta cell mass in 
the setting of diabetes. 
The cellular mechanisms regulating beta cell proliferation have been 
extensively studied and reviewed (Cozar-Castellano, Weinstock, et al. 2006).  
p21 is a Cdk inhibitor that is part of the CIP/KIP family subtype and has been 
suggested to function as a molecular brake during beta cell mass expansion. p21 
is upregulated in pregnancy and mitogen stimulation (e.g., HGF and placental 
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lactogen) to avoid excessive proliferation (Cozar-Castellano, Weinstock, et al. 
2006, Hughes and Huang 2011, Liu et al. 1996).  
In addition to its role in the beta cell, p21 has been studied in cancer 
biology and its expression is increased after DNA damage and cell stress (Gudas 
et al. 1995, Zhan et al. 1995). This rise in p21 occurs to halt proliferation and 
permit cell repair. However, if a cell becomes too damaged, its ultimate fate 
becomes apoptosis, a highly regulated form of cell death mediated through two 
distinct pathways, the extrinsic or intrinsic pathway, that converge upon activation 
of the effector caspase 3. Similarly, during the pathogenesis of diabetes, 
increased cellular stress, such as endoplasmic reticulum (ER) stress due to the 
increased secretory demand placed on the beta cell, could ultimately lead to 
apoptosis. Whereas p21 clearly plays a major role in halting proliferation in 
pancreatic beta cells, whether upregulation of p21 in beta cells directly 
contributes to the apoptotic death pathway in the development of diabetes 
remains to be determined. 
Here, we discovered that p21 is the only cell cycle inhibitor to be 
dramatically increased with two independent pharmacologic inducers of beta cell 
stress. The aim of this study was to gain more insight on the importance and 
function for the p21 upregulation during these processes. To this end, a p21-
overexpressing adenovirus was used to characterize the role of p21 on apoptosis 
and cell survival signaling within rodent beta cell lines and isolated pancreatic 
islets. 
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III.C. Results 
Dexamethasone and thapsigargin suppress proliferation and preferentially 
increase p21 transcription.  
Both dexamethasone and thapsigargin decreased proliferation in 832/13 
cells as indicated by a decrease in thymidine incorporation (Figure 4A). To 
determine the cell cycle inhibitor(s) responsible for the decrease in proliferation, a 
qPCR screen of the CIP/KIP and INK4/Arf family members was performed in 
832/13 cells (Figure 4B). Unexpectedly, p21 was the only cell cycle inhibitor 
markedly upregulated by both dexamethasone and thapsigargin. Whereas p27 
was significantly increased 2.7-fold with thapsigargin treatment, it was not 
induced by dexamethasone. These findings were verified in isolated rat islets and 
resulted in a nearly 3-fold increase in p21 transcripts with overnight treatment of 
dexamethasone or thapsigargin (Figure 4C). Transcripts for p15, p16, and p57 
were undetectable in 832/13 cells.  
To examine the dose- and time-dependent induction of p21 during the 
initiation of beta cell stress by thapsigargin, we treated 832/13 cells with 
increasing concentrations of thapsigargin and over a time course (Figure 5).  We 
used cleavage of caspase 3 as a readout of the development of beta cell stress-
mediated cell death.  The induction of p21 with increasing doses of thapsigargin 
largely mirrored that of caspase 3 activation/cleavage.  Interestingly, the time-
dependent induction of p21 by thapsigargin also coincided with the 
activation/cleavage of caspase 3. 
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Figure 4. 
   
 
Figure 4. Dexamethasone and thapsigargin halt proliferation and 
preferentially increase p21 transcription. 832/13 cells were treated with the 
vehicle DMSO (Control), dexamethasone (Dex, 100 nM for 16 h) or thapsigargin 
(Tg, 1 μM for 6 h). (A) Cell proliferation was assessed by [3H]-thymidine 
incorporation of triplicate samples, and (B) mRNA levels of cell cycle inhibitors 
were measured by qPCR. (C) p21 mRNA was measured in isolated rat islets 
treated overnight with vehicle, 1 µM Dex, or 10 μM Tg. Data are normalized to 
the DMSO-treated control group and are presented as means ± SEM; n = 3-5. * 
indicates significance versus Control using a one-way ANOVA test; p < 0.05. 
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Figure 5. 
 
Figure 5. Dose- and time-dependent upregulation of p21 transcription with 
thapsigargin. (A-C) 832/13 cells were treated with the vehicle DMSO (Control) 
or increasing doses of thapsigargin (250, 500, or 1000 nM) for 6 h. (D-F) 832/13 
cells were treated with thapsigargin (1000 nM) for 0.5, 1, 2, 4, or 6 h. (A, D) 
mRNA expression of p21 transcripts was measured by qPCR and expressed 
relative to Control. (B, E). Representative western blot of cleaved caspase 3 
protein (Cl casp-3) with each treatment and (C, F) quantified results normalized 
to actin expression.  Data are presented as means ± SEM; n = 3-4.  * indicates 
significance versus Control using a one-way ANOVA test; p < 0.05. 
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Cytokine stress does not induce p21 expression. 
Cytokine stress pathologically contributes to diabetes and the demise of 
functional beta cell mass. In an attempt to determine whether all forms of stress 
in beta cells upregulate p21 expression, 832/13 cells were co-treated with two 
proinflammatory cytokines, IL-1β and IFNɣ, both of which cause cytotoxicity in 
this cell type (Collier et al. 2006). After 6h and 24h of cytokine incubation, p21 
expression was not significantly induced as occurs with thapsigargin (Figure 6). 
 
p21 overexpression decreases beta cell proliferation and arrests the cell 
cycle at G1/S and G2/M transitions.   
To further investigate the role for p21 in beta cells, an adenovirus that 
overexpressed human p21, thus inhibiting cdk activation (Figure 7A-B), was 
used to transduce 832/13 cells and isolated rat islets. Expression of p21 was 
adenovirally increased approximately seven- and three-fold in 832/13 cells and 
rat islets, respectively (832/13 cells: 0.30 ± 0.01 vs. 2.21 ± 0.31 p21/actin, p < 
0.05; rat islets: 0.86 ± 0.25 vs. 2.34 ± 0.45 p21/actin, p < 0.05).  In both 832/13 
cells and rat islets, p21 overexpression decreased proliferation as indicated by 
tritiated-thymidine incorporation assays (Figure 7C-D). In addition, flow 
cytometry analysis revealed a significant decrease in the S phase cell population, 
but an increase in the G2 cell population (Figure 7E-F), consequently 
demonstrating cell cycle arrest at the G1/S and G2/M transitions. Unexpectedly, 
an increase in the sub-G0 cell population was also evident (Figure 7G) and led 
us to further investigate the role of p21 in apoptosis. 
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Figure 6. 
 
 
Figure 6. Proinflammatory cytokines do not induce p21 expression. 832/13 
cells were incubated with IL-1β, TNFα, and IFN for 6 or 24 h and compared to 
incubation with vehicle (Control). As a positive control, cells were incubated with 
1uM thapsigargin for 6 h. qPCR was used to measure mRNA expression of p21 
transcripts. Data are represented as mean ± SEM, n=4. * indicates significance 
from control, 6 h cytokines, and 24 h cytokines in a one-way ANOVA using 
Tukey’s post-hoc test. 
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Figure 7. 
 
 
 
 
 
Figure 7. p21-overexpressing adenovirus inhibits Cdk activation and entry 
into S and M phase. (A) Representative western blot of 832/13 cells transduced 
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with a control GFP- or p21-overexpressing adenovirus and probed for p21 and 
phosphorylated cyclin dependent kinase 1 (p-cdk1). (B) Quantification of 
phosphorylated cdk1 normalized to actin. * indicates significance versus GFP; n 
= 3 independent experiments. (C) 832/13 cells and (D) pooled rat islets of 3 
animals were treated with a control GFP- or p21-overexpressing adenovirus and 
[3H]-thymidine incorporation was measured to assess proliferation. Data are 
normalized to the control GFP group for [3H]-thymidine incorporation and 
presented as means ± SEM; n = 3-4 independent experiments in triplicate.  * 
indicates significance versus GFP in an unpaired or paired one-tailed t-test for 
832/13 cells and islets, respectively. (E) 832/13 transduced cells underwent flow 
cytometry and were analyzed by ModFit LT to acquire representative cell cycle 
peaks for each treatment and (F) to measure the percentage of cells at each cell 
cycle phase. (G) The percentage of sub-G0 cells were also acquired during this 
process. Data for cell populations are presented as means ± SEM, n = 4-5 
independent experiments with duplicate samples.  * indicates significance versus 
GFP in an unpaired two-tailed t-test, p < 0.05. 
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p21 directly activates apoptosis in beta cells.  
Using propidium iodide (PI) and annexin co-staining to sort apoptotic cells 
by flow cytometry (Figure 8A), overexpression of p21 was shown to decrease 
the percentage of viable cells (Figure 8B). Additionally, the number of annexin- 
and PI-positive cells was 7-fold higher with p21 overexpression, indicating a 
significant increase in the number of apoptotic cells (Figure 8C). Furthermore, 
protein analysis of 832/13 cells transduced with p21-overexpressing adenovirus 
demonstrated an increase in the hallmark apoptotic marker, cleaved caspase 3 
(Cl Casp3) (Figure 9A, 9C). More importantly, Cl Casp3 in isolated primary rat 
islets nearly tripled in p21 overexpression (Figure 9D, 9F). To determine whether 
p21 was disrupting cell survival signaling, levels of phosphorylated Akt (p-Akt) 
were assessed. Although there was a substantial decrease in p-Akt after p21 
overexpression in 832/13 cells (Figure 9A-B), this result did not translate to 
isolated islets under the experimental conditions used (Figure 9D-E).  
To determine if the induction of p21 during stress and p21’s ability to 
trigger apoptosis were novel phenomena in beta cells, we performed 
complementary experiments in HepG2 cells, a hepatocyte cell line. Thapsigargin 
but not dexamethasone induced p21 in HepG2 cells (Figure 10A). Interestingly, 
overexpression of p21 did not stimulate apoptosis in HepG2 cells; as a positive 
control to establish that HepG2 cells are capable of undergoing apoptosis, 
HepG2 cells were treated with the topoisomerase inhibitor etoposide, which also 
induces p21, and this treatment increased Cl Casp3 (Figure 10B).  Thus, the 
ability of p21 to induce apoptosis is dependent on the cellular context. 
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Figure 8. 
 
 
Figure 8. p21 overexpression increases the number of apoptotic beta cells. 
(A) Annexin-V and propidium iodide (PI) were used to co-stain GFP- or p21-
transduced 832/13 cells and sorted using flow cytometry. (B) Annexin- and PI-
negative cells are represented as viable cells. (C) Annexin- and PI-positive cells 
are represented as apoptotic cells. Data are presented as means ± SEM; n = 3 
independent experiments with duplicate samples. * indicates significance versus 
GFP in unpaired two-tailed t-tests; p < 0.05. 
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Figure 9. 
 
 
Figure 9. p21 overexpression activates caspase 3 and decreases cell 
survival. Representative western blot images from whole cell lysates of 832/13 
cells transduced with GFP- or p21-overexpressing adenovirus for 48 h (A) or rat 
islets transduced with the same adenoviruses for 72 h (D). Quantification of 
phospho Akt normalized to total Akt (B, E) and cleaved caspase 3 (Cl casp-3) (C, 
F), both normalized to actin protein, for lysates from 832/13 cells (B, C) and rat 
islets (E, F). Data are represented as mean intensities ± SEM, n = 3 experiments. 
* indicates significance versus GFP in an unpaired two-tailed t-test for 832/13 
cells and in a paired two-tailed t-test for islets, p < 0.05. 
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Figure 10. 
 
Figure 10. p21 upregulation does not activate caspase 3 in HepG2 cells. (A) 
HepG2 cells were treated with dexamethasone or thapsigargin (1 µM for 24 hr) 
and mRNA levels for p21 were measured by qPCR. (B) Representative western 
blot of HepG2 cells were transduced with GFP- or p21-overexpressing 
adenovirus or treated with etoposide (100µM for 6 or 24 h) as a positive control. 
Data are normalized to the DMSO-treated control group and are presented as 
means ± SEM; n = 3-4. * indicates significance versus Control using one-way 
ANOVA test; p < 0.05. 
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p21-induced apoptosis is mediated through the intrinsic mitochondrial 
death pathway.  
The next objective was to determine whether p21 was activating apoptosis 
through the extrinsic or intrinsic pathway. Protein analysis of caspase 8, an 
intermediate of the extrinsic pathway, indicated no change with p21 
overexpression (Figure 11A). mRNA expression of mitochondrial pro- and anti-
apoptotic bcl-2 family members that are regulated in the intrinsic pathway were 
not significantly different with p21 overexpression (Figure 11B). However, when 
utilizing 828/33 cells, a bcl-2 overexpressing beta cell line, p21-mediated 
caspase 3 cleavage was blocked (Figure 12A and 12D). Similarly, thapsigargin-
induced caspase 3 cleavage was also blocked in 828/33 cells despite persistent 
ER stress, as noted by the increase in phosphorylated eIF2α (Figure 12B and 
12E). Further, acute overexpression of Bcl-2 with a recombinant adenovirus 
attenuated p21-mediated caspase 3 cleavage (Figure 12C and 12F).  In 
addition, siRNA-mediated suppression of the pro-apoptotic Bax and Bak proteins 
also inhibited p21-mediated cell death as indicated by a decrease in caspase 3 
cleavage (Figure 13). The promotion of caspase 3 cleavage by p21 was 
mediated by both Bax and Bak, as siRNA-mediated suppression of either protein 
significantly reduced caspase 3 cleavage following p21 overexpression, and 
when both proteins were suppressed simultaneously, there was a further 
reduction in caspase 3 cleavage.  These data suggest that p21-induced 
apoptosis is mediated through the intrinsic mitochondrial death pathway.  
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Figure 11. 
 
 
Figure 11. p21-mediated apoptosis is not regulated through the extrinsic 
mitochondrial death pathway or by a change in Bcl-2 family member 
expression.  (A) Western blot analysis of caspase 8 (Cl casp-8) protein levels in 
whole cell lysates from 832/13 cells transduced with GFP- or p21-overexpressing 
adenovirus for 48 h. (B) These cells also underwent a qPCR screen of various 
pro- and anti-apoptotic Bcl-2 family transcripts. n = 3 independent experiments. 
  
62 
 
Figure 12. 
 
Figure 12.  p21- or ER stress-mediated apoptosis is blocked by Bcl-2 
overexpression. (A) 828/33 cells, which stably overexpress Bcl-2, were 
transduced with GFP- or p21-overexpressing adenovirus, and as a positive 
control 832/13 cells were transduced with p21-overexpressing adenovirus.  
Whole cell lysates underwent western blot analysis for Bcl-2, p21, cleaved 
caspase 3 (Cl casp-3) and actin as a loading control. (B) Quantification of 
cleaved caspase 3 normalized to actin. Data are represented as mean intensities 
± SEM, n = 3 independent experiments. * indicates significance versus 828/33 
cells transduced with GFP- or p21-adenovirus in a one-way ANOVA, p < 0.05.  
(C) Representative western blot of 828/33 and 832/13 cells treated with 
thapsigargin (Tg) for 6 h and probed for total and phosphorylated eIF2α to 
indicate ER stress, cleaved caspase 3 (Cl casp-3) to indicate ER stress-induced 
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apoptosis, and actin as a loading control. (D) Quantification of cleaved caspase 3 
normalized to actin. Data are represented as mean intensities ± SEM, n = 3 
independent experiments. * indicates significance versus 828/33 cells treated 
with vehicle or thapsigargin in a one-way ANOVA, p < 0.05.  (E) 832/13 cells 
were transduced with GFP-, Bcl-2-, or p21-overexpressing adenovirus for 48 h 
and caspase 3 activation was observed and (F) quantified via western blot 
analysis.  Data are represented as mean intensities ± SEM, n = 4 independent 
experiments.  * indicates significance between p21- and p21 + Bcl-2-adenovirus-
treated groups by ANOVA, p < 0.05.  # indicates significance versus GFP- and 
p21-adenovirus-treated groups by ANOVA, p < 0.05.  
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Figure 13. 
 
Figure 13.  p21-mediated apoptosis is blocked by siRNA-mediated 
suppression of Bax and/or Bak. (A) 832/13 cells were transfected with a 
scrambled control siRNA (siControl) or siRNAs directed against Bax (siBax), Bak 
(siBak), or the combination (siBax siBak) for 72 h and transduced with GFP- or 
p21-overexpressing adenovirus for the last 48 h of transfection for western blot 
analysis and quantification for cleaved caspase 3 (B, Cl casp 3), Bax (C), and 
Bak (D) protein normalized to actin. Data are represented as mean intensities ± 
SEM, n = 4 independent experiments. * indicates significance versus siControl + 
GFP in a one-way ANOVA test using Tukey’s post-hoc, p < 0.05. 
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III.D. Discussion 
During the development of type 2 diabetes, cellular stress impairs beta cell 
proliferation and function, promotes apoptosis, and ultimately triggers the demise 
of functional beta cell mass. Therefore, preservation of functional beta cell mass 
is essential to maintain euglycemia and prevent the transition from glucose 
intolerance/insulin resistance to frank diabetes. Various stressors known to 
influence functional beta cell mass during the progression to diabetes include 
inflammation, ER stress, free fatty acids, and glucotoxicity, to name a few 
(Donath et al. 2005).  However, the precise molecular events linking cellular 
stress to beta cell impairment and destruction are not fully understood. 
In an attempt to determine how a selection of stressors modulates 
functional beta cell mass and whether independent stressors converge on a 
uniform pathway, we initially focused on factors regulating cellular proliferation.  
We thus examined the inhibitory proteins of the cell cycle machinery during 
exposure to the synthetic glucocorticoid agonist dexamethasone, previously 
described as a beta cell stressor (Weinhaus et al. 2000), and a pharmacologic 
inducer of ER stress, thapsigargin. Both dexamethasone and thapsigargin 
reduced beta cell proliferation, and we speculated that the induction of p21 
mediates this response, as it was the only cell cycle inhibitory protein induced by 
both stressors. Using p21 overexpression in isolated primary rat islets and beta 
cell lines, we demonstrated that p21 is sufficient to inhibit proliferation by 
preventing the transition between the G1/S and G2/M phases of the cell cycle.  
The ability of p21 to prevent cell cycle transitions has been well established given 
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its ability to directly inhibit the activity of several cyclins and cdks, such as cdk1, 
necessary for cell cycle progression (Abbas and Dutta 2009). 
Several physiological and pathophysiological processes seem to converge 
on p21 as a mechanism to restrain beta cell growth. Previous work has 
implicated p21 as a molecular brake for beta cell proliferation during stimulation 
with mitogens, such as HGF and placental lactogen, to avoid excessive 
proliferation (Cozar-Castellano, Weinstock, et al. 2006). In addition to mitogen 
stimulation, endoplasmic reticulum (ER) stress models within beta cells increase 
p21 levels to inhibit proliferation (Yamada et al. 2006). 
Finally, treatment with glucocorticoids, shown here, also induces p21 and 
presumably limits beta cell proliferation.  Although it is counterintuitive that 
growth factors would induce the expression of a proliferation inhibitor, namely 
p21, a likely explanation is that these mechanisms are initiated to keep 
proliferation in check. Therefore, it is possible that negative feedback 
mechanisms of cell growth, proliferation, and survival signaling pathways are 
simultaneously activated.  This example of negative feedback by a cell cycle 
inhibitor in the beta cell is not exclusive of p21.  Pascoe and colleagues had 
previously demonstrated that free fatty acids, which themselves can drive beta 
cell replication, induce both p16 and p18 thereby blocking glucose-stimulated 
beta cell proliferation (Pascoe et al. 2012).  Together, these findings suggest that 
targeting cell cycle inhibitors may be warranted to maximize beta cell expansion 
as they serve as molecular brakes to growth-promoting stimuli. 
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While characterizing the role of p21 in proliferation, sub-G0 cells were 
notably higher leading us to further investigate p21 in beta cell death. Our 
findings conclude that p21 initiates apoptosis through the intrinsic apoptotic 
pathway, and the interplay between pro- and anti-apoptotic mitochondrial 
proteins are able to modulate the amount of p21-induced caspase 3 cleavage, a 
hallmark of apoptosis. Few studies have investigated the role of p21 in beta cell 
death. Interestingly, in a rat model of diabetes, isolated islets of 12-week old 
Zucker diabetic fatty rats had increased p21 mRNA transcripts that corresponded 
to a decrease in insulin mRNA (Kaneto, Kajimoto, Fujitani, et al. 1999). Although 
this study correlated decreased beta cells with an increase in p21, our 
experiments were able to directly establish that p21 itself is capable of acutely 
inducing apoptosis through the intrinsic pathway in beta cells, as we 
demonstrated increased caspase 3 cleavage with p21 overexpression, which 
could be inhibited by Bcl-2 overexpression or siRNA-mediated suppression of 
Bax or Bak. In support of our findings, chronically-induced p21-overexpressing 
mice exhibit hyperglycemia accompanied by increased apoptotic beta cells (Yang 
et al. 2009). Further, Blandino-Rosano and colleagues demonstrated that when a 
constitutively active form of Akt was overexpressed in vivo, which robustly 
increased beta cell replication and induced beta cell apoptosis, as measured by 
TUNEL staining, deletion of a single p21 allele attenuated the apoptosis 
(Blandino-Rosano et al. 2012).  Thus, chronic elevation of p21 leads to beta cell 
apoptosis and decreased levels of p21 are able to prevent it.  Beyond its level of 
expression, p21 localization is central to its function as triggering p21 localization 
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into the cytoplasm allows for its interaction with other molecules that are involved 
in stimulating apoptosis, such as JNK and even caspase 3 itself (Park et al. 
1998, Ranta et al. 2011). Despite its pro-apoptotic function in the beta cell, p21 
has had a conflicting role in apoptosis, and it has been suggested to also have 
anti-apoptotic actions depending on its subcellular localization (Gartel 2005, 
Koster et al. 2010, Vitiello et al. 2008, Warfel and El-Deiry 2013, Vitiello et al. 
2009). An explanation for these contradictory assertions could be that p21’s 
actions are cell type specific. Support for this idea is gained by our observation 
that p21 overexpression does not trigger apoptosis in a hepatocyte cell line, 
unlike its ability to do so in beta cells. 
One well-known cell survival signaling molecule is protein kinase B/Akt. 
Here we provide evidence that p21 overexpression inhibits phosphorylation of 
Akt in 832/13 beta cells. Previous studies have shown that Akt stabilizes p21 
protein expression when upregulated and that it is capable of binding to p21 
(Blandino-Rosano et al. 2012, Fatrai et al. 2006, Hughes and Huang 2011, Wu et 
al. 2011, Zhou et al. 2001). However, our findings suggest that p21 is able to 
negatively modulate Akt, indicating a possible feedback regulation. Further 
studies are necessary to determine the direct mechanisms for how p21 is able to 
attenuate Akt activation. Aside from reducing proliferation and cell survival 
signaling, our findings suggest that p21 is also mediating the death process that 
occurs as a result of excessive beta cell stress. 
In the beta cell, we have determined that p21 is transcriptionally 
upregulated under stress conditions. p21 overexpression in turn negatively 
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regulates cell proliferation and survival signaling while simultaneously inducing 
intrinsic apoptotic pathways in beta cells.  Undoubtedly, an increase in p21-
mediated apoptosis in the pancreatic islet would be damaging to beta cell 
function and the integrated insulin secretory capacity.  Decreasing the numbers 
of beta cells during states of insulin resistance or type 2 diabetes, would be 
detrimental to maintaining glucose homeostasis by compromising the ability to 
secrete insulin.  These findings suggest that inhibiting p21’s apoptotic role could 
be a useful therapeutic target to prevent beta cell death, although experiments to 
directly test this possibility remain to be completed. Additionally, further studies 
are necessary to determine the exact mechanism by which p21 induces the 
death pathway in beta cells.  Nevertheless, this work suggests a new mechanism 
for beta cell destruction during stress. 
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Chapter IV. Glucolipotoxicity-induced p21 suppresses pro-survival 
signaling in pancreatic beta cells 
 
IV.A. Synopsis 
T2D manifests from peripheral insulin resistance and a loss of functional 
beta cell mass due to decreased beta cell function, survival, or proliferation. The 
glucolipotoxic environment in the diabetic milieu activates a stress response in 
beta cells, resulting in decreased survival and programmed cell death through 
various mechanisms. One key mediator implicated in beta cell dysfunction is 
FOXO1, a transcription factor phosphorylated and inhibited by the pro-survival 
kinase Akt. Interestingly, palmitate in combination with high glucose induced 
expression of p21, a cell cycle inhibitor that activates the intrinsic apoptotic 
pathway and reduces Akt cell survival signaling. The molecular mechanism by 
which p21 activates apoptosis in beta cells during metabolic stress is still 
unknown. We hypothesized that p21-mediated suppression of Akt leads to 
FOXO1 activation, ultimately resulting in the expression of pro-apoptotic factors. 
To investigate the molecular events that p21 acts through to increase death and 
reduce cell survival, we overexpressed p21 with an adenoviral vector in isolated 
islets and 832/13 cells. p21 overexpression increased phosphorylation of the 
stress-activated protein kinase JNK. In contrast, FOXO1 phosphorylation was 
suppressed, indicating activation of FOXO1. Therefore, we propose that p21-
mediated inactivation of Akt leads to cell death via JNK and FOXO1 activation. 
Furthermore, p21 knockout mice were less susceptible to ER-stress induced cell 
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death. Our findings suggest a molecular mechanism by which metabolic stress- 
or glucolipotoxicity-induced p21 expression exacerbates beta cell death – a 
mechanism that could potentially be targeted to protect beta cell mass. 
 
IV.B. Introduction 
Increased intracellular free fatty acids in the presence of hyperglycemia, 
which is often found in cases of obesity, triggers a pathological process in the 
beta cells known as glucolipotoxicity. Mechanistically, glucolipotoxicity can 
induce a variety of processes deleterious to beta cells, including ER stress, 
inflammation, and oxidative stress. For example, mouse models of 
glucolipotoxicity such as high fat feeding exhibit increased ROS, inflammatory 
markers, and hallmarks of ER stress.  Because we demonstrated in the previous 
chapter that p21 is induced by ER stress in beta cells, we speculated that 
glucolipotoxicity might also induce p21.  Evidence from the literature in both 
human T2D and animal models of diabetes also suggest that p21 may be 
induced in response to overnutrition and the commensurate stress on the beta 
cell (Taneera et al. 2013, Keller et al. 2008, Dayeh et al. 2014).  The proposed 
induction of p21 in response to glucolipotoxicity would be likely to abrogate pro-
survival signaling, such as Akt signaling.  Identifying how pro-survival signaling is 
compromised with glucolipotoxicity could shed light on pathways that become 
impaired in T2D, thereby providing novel targets for protecting functional beta cell 
mass in the context of T2D pathogenesis.   
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One key mediator implicated in the loss of functional beta cell mass in the 
form of beta cell dysfunction is FOXO1, a transcription factor that regulates 
expression of target genes involved in cell death, reactive oxygen species 
detoxification, DNA repair, and cell cycle arrest (Carter and Brunet 2007). Insulin 
or growth factor signaling normally activates Akt, which then regulates FOXO1 
activity by phosphorylating FOXO1 to inhibit its nuclear localization. In the 
previous chapter we established that p21 overexpression reduces p-Akt. 
Therefore, it was hypothesized that p21 suppresses Akt, which then results in 
activation of FOXO1 in regulating its downstream target gene, Bim, a pro-
apoptotic BH3 domain containing protein. 
As the previous chapter focused on the induction of the cell cycle inhibitor 
p21 during ER stress in beta cells, the work here attempted to extend those 
findings to the clinically relevant scenarios of glucolipotoxicity and T2D. 
Therefore, the overall aim of the experiments in this chapter will focus on the role 
of p21 induction during glucolipotoxicity-induced ER stress, and investigation of 
the cellular pathways that are regulated by p21. As previously noted, 
overexpression of p21 inhibits Akt activation. Therefore, we propose that p21 is 
induced by glucolipotoxicity and results in the activation of stress pathways and 
the reduction of Akt downstream cell survival pathways. 
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IV.C. Results 
 
High fat feeding induces p21. 
High fat feeding in C57BL/6 mice has been used as a model for pre-
diabetes as it promotes the normal beta cell compensatory responses thought to 
occur in the pathogenesis of human T2D.  If beta cell compensation is prevented 
such as in the BTBR mouse (Keller et al. 2008) or mice lacking one allele of 
Pdx1 (Johnson et al. 2003) or both insulin receptor alleles (Kulkarni et al. 1999), 
mice go on to develop frank T2D.  Identifying mechanisms that prevent beta cell 
compensation are essential to preserving glucose homeostasis in the face of 
systemic insulin resistance.  Thus, we examined the expression of p21 in a 
microarray experiment with islets from mice fed either a standard chow or 42% 
high fat diet.  Interestingly, p21 was elevated in the islets from high fat fed mice 
compared to the chow-fed controls (Figure 14).  
 
Glucolipotoxicity induces ER stress, cell death, and p21 expression.   
Others have reported that glucolipotoxicity-induced beta cell death is 
mediated through severe ER stress and is reduced in Bim knockout mice ex vivo 
(Wali et al. 2014). Our previous findings indicate that p21 transcription is induced 
by ER stress in beta cells. Therefore, we aimed to determine whether 
glucolipotoxicity-mediated ER stress also upregulates p21. In agreement with 
previous studies, glucolipotoxicity in beta cells activates ER stress as is evident 
by the increase in spliced Xbp1 (Xbp1-s) and CHOP expression (Figure 15A-B). 
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Furthermore, cellular stress and death were present after glucolipotoxicity, which 
resulted in the phosphorylation of the stress kinase c-jun N-terminal kinase (p-
JNK) (Figure 15C, 15D). Increased cell death was measured by the abundance 
of cleaved caspase 3, which was significantly increased by 4 h of 
glucolipotoxicity (Figure 15D-E). Importantly, glucolipotoxicity also induced p21 
expression (Figure 15F). 
 
p21 overexpression activates eIF2α but does not activate ER stress  
To further investigate the role of p21 in beta cell stress, an adenovirus that 
overexpressed human p21 was used to transduce 832/13 cells. Interestingly, p21 
overexpression resulted in an increase of p-eIF2α (Figure 16A-B). To determine 
whether or not p21 directly activates ER stress, we also examined the expression 
of Xbp1-s. Whereas thapsigargin, a chemical inducer of ER stress, dramatically 
upregulated Xbp1-s (Figure 16C), p21 overexpression did not increase Xbp1-s 
but rather decreased its expression (Figure 16D). Therefore, p21 itself does not 
activate ER stress, but rather ER stress induces p21 expression.  
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Figure 14. 
 
 
 
Figure 14. p21 transcripts are elevated under stress in vivo. Microarray 
analysis of islets from C57BL/6 mice fed normal chow or 42% high fat diet (HFD) 
for 16 weeks. p < 0.05 ANOVA and Tukey’s post-hoc. Data courtesy of Dr. Evans-
Molina and Dr. Mirmira laboratories (Sims et al. 2013). 
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Figure 15. 
   
 
   
Figure 15. Glucolipotoxicity activates ER stress, the stress kinase JNK, and 
p21 expression. 832/13 cells were treated with 1% BSA in either 5 mM glucose 
for 8h (LG) or in 20 mM glucose for 8h (HG) and compared to 400 M palmitate 
in 20 mM glucose at various time points as stated above or for 2 h (GLT). qPCR 
was used to measure mRNA expression of (A) spliced Xbp1 (Xbp1-s) and (B) 
A. B. 
C. D. 
E. F. 
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CHOP. (C) Quantitative analysis of phosphorylated JNK (p-JNK) and a (D) 
representative western blot of p-JNK and cleaved caspase 3 (Cl casp 3). (E) 
Quantitative analysis of Cl casp 3 normalized to actin. (F) qPCR was used to 
quantify p21 gene expression. Data represented as means ± SEM; n = 3-4. 
*significance vs. LG BSA in one-way ANOVA using Tukey’s post hoc; p < 0.05. 
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Figure 16. 
    
 
 
Figure 16. p21 overexpression activates eIF2α but does not induce ER 
stress. 832/13 cells were transduced with an adenovirus overexpressing GFP or 
p21 for 48 h. Shown are (A) a representative western blot for phosphorylated (p-
eIF2α) and total eIF2α (B) and quantified results relative to total eIF2α protein. 
qPCR was used to measure mRNA levels of spliced Xbp1 (Xbp-1s) in 832/13 
cells that were (C) treated with DMSO control or thapsigargin for 6 h, or  (D) 
transduced with GFP- or p21-overexpressing adenovirus.
p-eIF2α 
eIF2α 
eIF2α Total eIF2α 
GFP p21 
Actin 
832/13 cells: 
A. B. 
C. D. 
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p21 overexpression activates JNK preceeding cell death. 
Similar to the observations from glucolipotoxic conditions, p21 
overexpression increased p-JNK in isolated mouse islets (Figure 17A-B) and 
832/13 cells (Figure 17C). We next investigated whether p21-mediated caspase 
3 cleavage was necessary to activate JNK – i.e., did death beget heightened 
stress kinase signaling? To test this, we utilized the Bcl-2 overexpressing 828/33 
rat beta cell line, which inhibits p21-mediated caspase 3 cleavage (Hernandez et 
al. 2013). We found that p21 overexpression in this cell line results in similar 
activation of p-JNK, despite the absence of cleaved caspase 3 (Figure 17C-
17D). Therefore, we conclude that the activation of this stress responsive kinase 
occurs before p21-mediated cell death. 
 
ER-stress induced cell death, but not p21-induced cell death, is dependent 
on the JNK pathway. 
Previous evidence suggests that the JNK pathway is necessary to induce 
glucolipotoxicity-induced death and ER-stress mediated deleterious effects on 
beta cell function (Ozcan et al. 2004, Martinez et al. 2008). To verify these 
findings, we utilized a dominant negative JNK1 (JNK-DN)-overexpressing 
adenovirus to inhibit the JNK pathway in 832/13 cells. JNK activity was measured 
by quantifying the amount of phosphorylated c-Jun (p-c-Jun), a well-known JNK 
target protein. Upon thapsigargin treatment, JNK-DN overexpression resulted in 
a decrease of p-c-Jun compared with thapsigargin treatment alone (Figure 18A). 
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Additionally, JNK-DN overexpression blunted thapsigargin-induced caspase-3 
cleavage (Figure 18B). 
To determine whether activation of JNK is necessary for p21-mediated 
death, we used a JNK inhibitor, SP600125, to inhibit JNK (Figure 19A).  
Although JNK activity was inhibited, as is evident by the decreased 
phosphorylation of c-Jun (Figure 19B), p21-mediated cell death was not reduced 
(Figure 19B-C). Because multiple stress kinases are activated during stress, we 
used a p38 MAPK inhibitor in combination with the JNK inhibitor (Figure 20). In 
this case, cell death in response to p21 overexpression persisted and was not 
inhibited with either the p38 inhibitor, JNK inhibitor, or the combination of the two 
inhibitors. These data suggest that although p21 activates stress and kinases 
such as JNK, p21-mediated death is not solely dependent on their downstream 
signaling.
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Figure 17. 
               
 
  
 
Figure 17. p21 overexpression induces phosphorylation of JNK prior to cell 
death. Shown are a representative Western blot analysis and quantification of p-
JNK in GFP- or p21-overexpressing mouse islets (A-B, respectively). (C) 832/13 
or 828/33 cells were transduced with adenoviruses for 72 or 48 h, respectively. 
(D) Quantification of p-JNK was normalized to total JNK/actin. Data are 
represented as means ± SEM; n=3-4. * indicates significance vs GFP; p < 0.05. 
A. B. 
C. D. 
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Figure 18. 
 
 
 
Figure 18. Dominant negative JNK1 inhibits ER stress-induced cell death. 
832/13 cells were transduced with a GFP- or a dominant negative JNK1 (JNK-
DN) for 16 h and underwent 1 M thapsigargin treatment for the last 6 h. (A) 
Representative western blot image of cleaved caspase 3 (Cl Casp3), p-cJun, 
total JNK, and actin as a loading control. (B) Quantification of Cl Casp3 protein. 
Data represented as mean ± SEM, n=4. * indicates significance vs. DMSO 
treated GFP-overexpressing cells, # indicates significance vs. Thapsigargin 
treated GFP-overexpressing cells.  
A. 
B. 
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Figure 19. 
 
    
Figure 19. p21-mediated cell death is not dependent on the JNK pathway. 
GFP- or p21-overexpressing adenovirus was used to transduce 832/13 cells for 
48 h. At the same time, the JNK inhibitor SP600125 or DMSO were used to treat 
cells every 8 h during the 48 h transduction period. (A) Representative western 
blot image of p21, p-JNK, total JNK, cleaved caspase 3 (Cl casp3), and actin. 
Quantitative analysis of (B) phosphorylated c-Jun (p-c-Jun) protein and (C) 
cleaved caspase 3 protein. Data are represented as means ± SEM. * indicates 
significance vs. GFP DMSO and # indicates significance vs. p21 DMSO in a two-
way ANOVA using Tukey’s post-hoc test. 
DMSO SP600125 
- 
 
GFP p21 GFP p21 
pJNK 
Cl casp3 
Total JNK 
p21 
Actin 
- 
A. 
B. C. 
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 Figure 20. 
 
 
 
Figure 20. p21-mediated cell death is not dependent on the JNK nor p38 
MAPK pathways. The p38 MAP Kinase inhibitor (p38i) PD169316 was freshly 
added every 8 h alone or in combination with the c-Jun Kinase inhibitor (JNKi) 
SP600125 in conditions of either GFP or p21 overexpression. This figure depicts 
the quantitative analysis of a western blot for cleaved capase 3 normalized to 
actin. Data are represented as means ± SEM. * indicates significance vs GFP 
DMSO. 
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Similar to glucolipotoxicity, p21 overexpression negatively regulates 
insulin signaling. 
We next queried whether the induction of p21 during beta cell stress 
influences classical cell survival mechanisms. Growth factor signaling and insulin 
signaling both contribute to enhanced proliferation and survival of beta cells 
(Kasuga 2006, Alejandro 2010, Beith 2008). Therefore, we examined insulin 
receptor substrate (IRS1), a key mediator of insulin signaling. We observed a 
reduction of phosphorylated IRS1 with p21 overexpression (Figure 21A, 21C). 
Although high glucose stimulates increased IRS1 activation, we observe a similar 
decrease in activation of IRS1 with glucolipotoxicity (Figure 21B, 21D). Our 
previous findings also suggest that the downstream Akt activation is also reduced 
with p21 overexpression (Hernandez et al. 2013). These findings suggest a 
similar pattern between glucolipotoxicity- and p21-mediated cell death as they 
both increase stress kinase responses, while decreasing insulin signaling.  
 
Upregulation of p21 in 832/13 beta cells impairs glucose-stimulated insulin 
secretion. 
As p21 overexpression impaired insulin signaling, we explored the idea 
that this effect could be attributable to impaired insulin secretion, which would 
lead to decreased autocrine/paracrine activation of the insulin receptor and 
commensurate downstream signaling. As predicted, p21 overexpression 
completely blunted GSIS (Figure 22A). However, it is important to consider that 
the impaired GSIS could be due to increased cell death evident with p21 
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overexpression – i.e., a dying beta cell would be unable to appropriately secrete 
insulin. Therefore, 828/33 cells, which are resistant to p21-mediated cleaved 
caspase-3/apoptosis, were utilized to rule out death as a contributing factor to 
impaired GSIS. p21 overexpression again completely impaired GSIS, even 
without the increase in cell death (Figure 22B). Therefore, the upregulation of 
p21 during stress conditions not only induces intrinsic apoptosis, but it also 
impairs beta cell function.  
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Figure 21. 
  
   
Figure 21. Insulin signaling is reduced during p21- and glucolipotoxicity-
mediated stress. 832/13 cells were either (A,C) transduced with GFP- or p21-
overexpressing adenovirus, or (B,D) treated with glucolipotoxicity for 2, 4, 6, or 8 
h. (A-B) Representative western blot of phosphorylated IRS1 (p-IRS1) at S636. 
Quantitative analysis of p-IRS1 protein during (C) GFP- vs p21-overexpression, 
or (D) BSA in 25 mM glucose-containing media (HG BSA) vs 400 M palmitate in 
25 mM glucose-containing media (GLT; 4 h). Data are represented as means ± 
SEM, n=4. * indicates significance vs.GFP or HG BSA, p<0.05.  
* 
p-IRS1 
Actin 
GFP p21 
832/13 cells 
A. B. 
C. D. 
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Figure 22. 
 
 
Figure 22. Upregulation of p21 impairs glucose-stimulated insulin 
secretion. (A) 832/13 or (B) 828/33 cells were transduced with GFP- or p21-
overexpressing adenovirus for 45 h and underwent a GSIS assay. The 
incubation buffer from cells was collected after 1 h with exposure to either 2.5 or 
15 mM glucose to measure insulin secretion with a radioimmunoactivity assay. 
Data are represented as means ± SEM, n=3.  * indicates significance vs. 2.5 mM 
glucose, # indicates significance vs GFP at 15 mM glucose, p<0.05.  
A. B. 
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p21 overexpression reduces FOXO1 phosphorylation and activates 
expression of its pro-apoptototic target gene, Bim. 
Insulin (and other growth factor) signaling leads to the activation of Akt to 
trigger downstream cell survival pathways. One immediate downstream action of 
Akt is to inhibit FOXO1, a transcription factor that is implicated as a key mediator 
of glucolipotoxicity-induced beta cell stress (Okamoto et al. 2006). FOXO1 
transcriptionally activates the expression of the Fas ligand (Fas-L) and the BH3 
domain containing Bim, both of which activate apoptosis (Carter and Brunet 
2007). Fas-L specifically activates the extrinsic apoptotic pathway, whereas Bim 
is a mediator of both the intrinsic and extrinsic apoptotic pathways. As we have 
shown previously that p21 activates the intrinsic and not the extrinsic apoptotic 
pathway, we thus decided to assess Bim expression. Due to the fact that p21 
overexpression reduces insulin signaling and Akt phosphorylation, we predicted 
that FOXO1 is activated during p21-mediated stress, similar to that which occurs 
with glucolipotoxic stress. We observed that p21 overexpression in the 832/13 
beta cell line significantly decreased FOXO1 phosphorylation (Figure 23A-B) 
and its pro-apoptotic target Bim (Figure 23C). As expected, glucolipotoxicity also 
decreased Fox-O1 phosphorylation (Figure 24A-B) and activated gene 
expression of Bim (Figure 24C). These findings again show that glucolipotoxicity 
and p21 overexpression show similar effects on cell signaling pathways. 
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Figure 23. 
   
      
      
Figure 23. p21 overexpression reduces phosphorylation of FOXO1 and 
activates expression of its target gene, Bim. (A) Western blot analysis of 
phosphorylated FOXO1 (p-FOXO1) from GFP- or p21-overexpressing 832/13 
cells that were transduced for 48 h. (B) Quantification of p-FOXO1 was 
normalized to total FOXO1. (C) qPCR was used to analyze Bim expression in 
GFP- or p21-overexpressing 832/13 cells. Data are represented as mean ± SEM, 
n=3-4. * indicates significance v.s GFP in a student’s t-test; p < 0.05. 
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Figure 24. 
 
  
Figure 24. Glucolipotoxicity reduces phosphorylation of FOXO1 and 
activates Bim expression. 832/13 cells were treated with 1% BSA in either 5 
mM glucose (LG) or in 20 mM glucose (HG) and compared to cells treated with 
400 M palmitate in 20 mM glucose (GLT). Various treatment times were used 
as indicated or for 2 h with GLT. (A) Representative western blot images and (B) 
quantification of FOXO1 (p-FOXO1) normalized to total FOXO1/actin are shown. 
(C) qPCR was used to measure gene expression of Bim. Data are represented 
as mean ± SEM, n=3-4. *indicates significance vs. LG BSA in a one-way ANOVA 
using Tukey’s post hoc, p < 0.05. 
  
A. 
B. C. 
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p21-mediated cell death is independent of Bim expression. 
Recent studies provide evidence that glucotoxicity-induced cell death is 
reduced in Bim knockout mice (Wali et al. 2014), suggesting that Bim expression 
is partially responsible for glucolipotoxicity- and ER stress-induced death. 
Furthermore, Bim expression is upregulated in human islets of patients with T2D. 
Because upregulation of p21 induced Bim expression, we tested whether Bim 
was necessary for p21-mediated cell death. Using siRNA-mediated suppression 
of Bim in conjunction with adenovirally-mediated p21 overexpression, we found 
that although there was sufficient knockdown of Bim expression (Figure 25A, 
25C), p21 overexpression still induced the same amount of cell death as 
measured by cleaved caspase 3 protein (Figure 25B, 25D). These data indicate 
that Bim is not required for p21-mediated cell death. 
 
p21 is necessary for ER-stress induced cell death. 
 Both glucolipotoxicity- and thapsigargin-induced ER stress upregulate p21. 
Thus we determined the extent to which p21 is necessary for ER-stress induced 
cell death. Using p21 knockout mice (p21 KO), we treated their islets ex vivo with 
thapsigargin and observed no difference in ER stress response as indicated by 
similar CHOP expression (Figure 26A). However, when examining apoptosis via 
a DNA fragmentation assay, thapsigargin treated wild-type islets resulted in a 
2.5-fold increase in apoptosis, whereas in p21 KO islets, we observed a blunted 
thapsigargin-induced cell death response (Figure 26B). These data suggest that 
p21 required, in part, for thapsigargin-induced cell death in beta cells.
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Figure 25. 
 
      
Figure 25. Bim suppression does not reduce p21-mediated cell death. 
832/13 cells underwent siRNA-mediated suppression of Bim in the presence of 
either a GFP- or p21-overexpressing adenovirus. (A) Representative western blot 
image of Bim protein and (C) qPCR of Bim gene expression are shown. (B) 
Representative western blot image of cleaved caspase 3 (Ccasp3) and (D) 
quantitative analysis of Ccasp3 protein are also shown. Data are represented as 
means ± SEM, n=4. * indicates significance vs siControl + GFP-overexpressing 
adenovirus, # indicates significance vs siControl + p21-overexpressing 
adenovirus, p<0.05.   
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Figure 26.  
  
Figure 26. p21 knockout mice exhibit lower ER-stress induced death. 
Isolated mouse islets from homozygous p21 wild-type (WT) or knockout (KO) 
mice were treated with DMSO or 10 M thapsigargin (Tg) for 48 h. qPCR was 
used to measure (A) CHOP gene expression. (B) Additionally, an ELISA Cell 
Death assay was used to quantify DNA fragmentation in WT or p21 KO mice. 
Data are represented as mean ± SEM, n=4 for each genotype. * indicates 
significance vs DMSO within genotype, # indicates significance vs WT treated 
with Tg, p<0.05. 
A. B. 
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IV.D. Discussion 
Most individuals with T2D and even late pre-diabetes have elevated 
circulating glucose levels and impaired insulin-mediated inhibition of lipolysis, 
creating a glucolipotoxic milieu within the individual. Glucolipotoxicity in the 
pancreatic beta cell can lead to the demise of beta cell function and beta cell 
mass. In fact, death of beta cells is triggered by glucolipotoxicity as the increased 
lipids incorporate into the ER membrane and in combination with high glucose, 
activate the UPR, the production of ROS, and the induction of inflammation. In 
addition, glucolipotoxicity impairs beta cell function and insulin secretion. In our 
findings, we confirm that glucolipotoxicity indeed activates ER stress, leads to 
increased phosphorylation of stress responsive kinases, and impairs insulin and 
cell survival signaling. Interestingly, we also discovered that glucolipotoxicity 
induces expression of the cell cycle inhibitor, p21. 
Glucolipotoxicity is one of many insults that the beta cell faces during 
course of diabetes, and it is important to determine similarities between the 
mechanisms leading to cell death in order to find new therapeutic approaches to 
protect beta cells from these insults. Our previous findings demonstrated that 
other beta cell stressors, such as glucocorticoid receptor activation by 
dexamethasone and ER stress by the SERCA inhibitor thapsigargin, both also 
upregulated p21 expression. Additionally, both chronic high glucose and 
intermittent high glucose also induce p21 expression (Zhang, Li, et al. 2014). In 
further support, p21 mRNA was significantly increased in a microarray analysis of 
islets from mice fed a high fat diet compared to mice on chow diet (Sims et al. 
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2013). Therefore, under a cadre of diverse stress conditions, p21 is upregulated 
in the beta cell.   
Similar to glucolipotoxicity, p21 overexpression activates the stress 
responsive JNK at the earliest time point examinined (i.e., 2 h).  As previously 
described, phosphorylation of JNK is an early event that diminishes over time 
and occurs within 1 h of high concentrations of the fatty acid palmitate (Martinez 
et al. 2008). Therefore, JNK is an early participant of glucolipotoxicity-induced 
signaling that leads to beta cell death. Interestingly, inhibitors of JNK reduced 
glucolipoxity-induced caspase 3 cleavage (Martinez et al. 2008). However, in the 
work presented here, inhibition of JNK did not blunt p21-mediated cell death. 
This suggests that p21 overexpression activates JNK, an upstream event to 
death that could influence other cellular signals. The insulin signaling pathway is 
one that is reduced by the activation of JNK, and is reversed when JNK is 
inhibited (Nguyen et al. 2005). Thus, we decided to further investigate the 
influence of p21-mediated JNK activation on the insulin signaling pathway. 
Our findings show that p21 overexpression also reduced insulin signaling, 
and specifically reduced p-IRS1 and p-Akt.  Interestingly, JNK inhibits IRS-1 by 
associating with it and phosphorylating the Serine 307 site to promote insulin 
resistance (Aguirre et al. 2000). Thus, further studies could determine whether 
this event is occurring during conditions of p21 upregulation. Given that the 
insulin signaling pathway is diminished during p21 overexpression, we postulate 
that this is one primary mechanism by which p21 increases beta cell death.  
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We next investigated whether the impaired insulin signaling could be 
attributed to changes in the upstream GSIS under these conditions. Observations 
indicate that aside from activation of stress kinases and impaired insulin 
signaling, upregulation of p21 in beta cells resulted in impaired GSIS. However, 
the exact mechanism of p21’s action to impair GSIS remains to be determined. 
Akt activation enhances cell survival signaling by inhibiting FOXO1 
nuclear import where it can transactivate expression of pro-apoptotic proteins 
such as Bim and FASL. Although FOXO1 can confer stress resistance during 
JNK activation (Matsumoto and Accili 2005), chronic FOXO1 activation is part of 
the mechanism for glucolipotoxicity of beta cells (Martinez et al. 2008, Banks et 
al. 2011, Accili and Arden 2004). Here, we discovered that like glucolipotoxicity, 
p21 overexpression resulted in a decrease in the Akt-phosphorylated site on 
FOXO1. Therefore, FOXO1 is capable of nuclear import and activation of 
transcriptional activity. However, FOXO1 transcriptional activity is yet to be 
measured during p21 overexpression.  
In our findings, we also discovered that the BH3 domain-containing protein 
Bim, a FOXO1 target gene, is upregulated during glucolipotoxicity and p21 
overexpression. Interestingly, islets of Bim knockout mice are partially protected 
from glucotoxicity and along with another proapoptotic BH3-only protein Puma, is 
postulated as one of the downstream effectors glucotoxicity-induced ER stress 
and mitochondrial oxidative stress (Wali et al. 2014). Although our experiments 
using Bim knockdown cells did not show protection from p21-mediated cell 
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death, induction of Bim could be one of multiple effectors that p21 acts on that 
contributes to the demise of beta cells. 
An important discovery from this work is that knockout of p21 partially 
protects from cell death in response to increased ER stress. In other cell types, 
p21 has been linked to an anti-apoptotic role; however, in beta cells, our findings 
lead us to the proposed model where beta cell stressors upregulate p21 
expression to act on multiple effectors that lead to the demise of function and 
survival (Figure 27). Specifically, the upregulation of p21 in beta cells is partially 
responsible for the activation of JNK, FOXO1, and Bim expression, whereas at 
the same time contributes to the inhibition of insulin signaling and IRS-1, and 
including the downstream cell survival signaling through Akt. Overall, we 
demonstrated that aside from its classical role of halting proliferation, p21 impairs 
beta cell function, inhibits beta cell survival, and activates pro-apoptotic signaling 
pathways. 
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Figure 27. 
 
 
Figure 27. Proposed model of p21-mediated regulation of beta cell function 
and survival. p21 is upregulated under beta cell stress conditions and is partially 
responsible for halting beta cell proliferation, blunting insulin secretion, inhibiting 
insulin signaling, and activating stress responses that lead to apoptosis. 
Specifically, p21 reduces a key regulator of cell survival, Akt, which then allows 
for expression of FOXO-1’s pro-apoptotic gene target, Bim. In addition, p21 
induces phosphorylation of the stress activated kinase, JNK. Both Bim and JNK 
induce apoptosis mediated through cleaved caspase 3. Negative regulation is 
depicted in red, and positive regulation is depicted in green. 
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Chapter V. Conclusions, Perspectives, and Future Studies 
 
V.A. Conclusions and Perspectives 
The main conclusions from this dissertation project are that multiple 
stressors in the beta cell upregulate p21 expression and that p21 contributes to 
ER-stress induced intrinsic apoptosis by regulating effectors of the cell survival 
and cell death pathways. Although the specific mechanism by which p21 
regulates these effectors still remains unclear, the findings from my work suggest 
that p21’s actions occur downstream of ER stress but upstream of the activation 
of the stress kinases and/or inhibition of insulin signaling and impaired beta cell 
function. 
Stressors such as cytokines, glucocorticoids, and gluco(lipo)toxicity, 
contribute to beta cell destruction through various and sometimes overlapping 
mechanisms. My thesis demonstrates that dexamethasone, thapsigargin, and 
glucolipotoxicity, which have distinct modes of action to induce beta cell stress, 
all induce p21 expression. Stress responses activated in dying beta cells include 
inflammation, ER stress, and ROS. Although my primary work investigated ER 
stress, others found that reactive oxygen species also induce p21 expression in 
beta cells (Kaneto, Kajimoto, Fujitani, et al. 1999). Another noteworthy finding is 
that 832/13 cells incubated with proinflammatory cytokines did not induce p21 
expression. This result signifies that not all mechanisms of stress-induced beta 
cell death, such as inflammation, are regulated by p21. However, with my 
findings and those of others (Kaneto, Kajimoto, Fujitani, et al. 1999, Taneera et 
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al. 2013, Hughes and Huang 2011, Ranta et al. 2011, Tarry-Adkins et al. 2009, 
Yamada et al. 2006, Zhang et al. 1999, Zhang, Li, et al. 2014), p21 is a common 
factor among numerous stressors that warrants further investigation. 
The major finding for Chapter III is that p21 activates the intrinsic apoptotic 
pathway rather than the extrinsic pathway. During the first screen of 
mitochondrial proteins of the Bcl-2 family, we did not identify any changes in 
expression of these proteins with p21 overexpression. However, we later 
determined in Chapter IV that Bim, which was not included in the original screen, 
is a mitochondrial protein in the Bcl-2 family that is upregulated with p21 
overexpression. Therefore, my findings suggest that p21 is activating the intrinsic 
pathway via upregulation of Bim expression. However, we later determined that 
knockdown of Bim alone was unable to block p21-mediated cell death. 
Bim is a BH3 domain-only pro-apoptotic protein, like Bax and Bak. 
Although Bim does not have the capability for pore formation on the 
mitochondrial membrane, unlike Bax and Bak, it is able to anchor onto the 
mitochondrial membrane to antagonize Bcl-2 (Gross, McDonnell, and Korsmeyer 
1999). Both glucolipotoxicity and p21 overexpression induce Bim expression. 
Interestingly, we found that knockdown of Bim was not sufficient to inhibit p21-
mediated caspase 3 cleavage. However, overexpression of Bcl-2 was sufficient 
to block p21-mediated cell death. Furthermore, knockdown of Bax and Bak, the 
pore forming mitochondrial proteins, also reduce p21-mediated death. This 
suggests that by knocking down Bim, p21 is still able to stimulate pore formation 
independent of Bim at the membrane and that p21 mediated death is dependent 
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on the pore forming unit. The studies I performed to investigate expression of 
these proteins on the mitochondrial membrane were inconclusive due to 
technical difficulties, however, I suspect that although transcription of Bcl-2, Bax, 
and Bak did not change, their translocation to the mitochondrial membrane are 
dynamically regulated during conditions of p21 overexpression. 
The studies from Chapter III also hinted towards findings of decreased cell 
survival signaling, as indicated by the decrease in phosphorylated Akt under 
conditions of p21 overexpression. We dove a little deeper into the insulin 
signaling pathway in Chapter IV and found that p21 overexpression also 
decreased phosphorylated IRS-1, a substrate upstream of Akt and downstream 
of the insulin receptor. This led us to examine GSIS as a possible explanation for 
the reduced insulin and pro-survival signaling. Overexpression of p21 indeed 
impaired GSIS in both the 832/13 and 828/33 beta cells. The 828/33 cells are 
resistant to p21-mediated cell death and thus allowed us to examine p21-
mediated impairments of GSIS independent of death-associated impairments of 
GSIS. Interestingly, previous work by others determined that p21 inhibits insulin 
gene expression and GSIS (Kaneto, Kajimoto, Fujitani, et al. 1999, Dayeh et al. 
2014). It would be ideal to verify whether insulin content or gene expression is 
regulated by p21.  
Due to the fact that glucolipotoxicity is classically known to activate 
FOXO1, and the fact that it is an immediate downstream target of Akt, I next 
examined FOXO1. Chronically activated FOXO1 is responsible for the production 
of pro-apoptotic proteins. Findings in Chapter IV verify that FOXO1 is activated 
103 
 
with both glucolipotoxicity and p21 overexpression, as measured by decreased 
FOXO1 phosphorylation. Others have indicated that FOXO1 can also be 
activated by acetylation (Banks et al. 2011, Qiang, Banks, and Accili 2010). It 
would be interesting to determine whether p21 regulates the acetylation of 
FOXO1 as well. Previous studies by Martinez et al. show that the activation of 
FOXO1 with glucolipotoxicity is associated with translocation of FOXO1 into the 
nucleus (Martinez et al. 2008). In order to determine whether the influence of p21 
on FOXO1 activation is critical for the pro-apoptotic effect of p21, it would be 
ideal to overexpress the dominant negative form of FOXO1 in the presence of 
p21 overexpression, or alternatively utilize beta cell speficic FOXO1 knockout 
mice. If p21-mediated cell death is reduced under such conditions, this would 
suggest that FOXO1 activation is essential to the pro-apoptotic mechanism of 
p21. 
In our studies that examined whether p21-mediated death was dependent 
on JNK activation, we used SP600125, a selective and reversible JNK1, -2, and -
3 inhibitor that works by competing with ATP to inhibit the phosphorylation of c-
Jun (Bennett et al. 2001). One caveat to these studies is that although we saw 
decreased phosphorylation of the JNK target protein c-Jun, we did not see a 
significant decrease in p-JNK, indicating that there was still some active JNK 
available for signaling. An alternative approach to solve this issue is to use a 
dominant negative JNK (DN-JNK1) in 832/13 cells to inhibit JNK functionality.  
Our recent findings show that DN-JNK1 inhibited thapsigargin-induced cell death. 
The next step would be to determine whether active JNK is necessary for p21-
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mediated cell death. These future experiments would give either verification of 
our previous results or lead to further insight on the mechanistic details of p21 
action after stressful insults within the beta cell. 
Importantly, we have shown both similarities and differences in the cellular 
events that occur with thapsigargin-, glucolipotoxicity- and p21 overexpression-
induced beta cell stress. Specifically, thapsigargin and p21 overexpression both 
halt proliferation, lead to phosphorylation of eIF2α, and induce cleaved caspase 3 
in 832/13 cells. Similiarly, in 828/33 bcl-2 overexpressing cells, thapsigargin and 
p21 overexpression lead to elevated phosphorylation of eIF2α and a blockage of 
cleaved caspase 3. Additionally, thapsigargin treatment, glucolipotoxicity, and 
p21 overexpression lead to phosphorylation of JNK and upregulation of CHOP 
expression. On the contrary to thapsigargin- and glucolipotoxicity-induced beta 
cell stress, p21 overexpression does not increase spliced Xbp-1. Lastly, inhibiting 
JNK activation reduces thapsigargin-induced cleaved caspase 3, whereas JNK 
inhibitors did not inhibit p21 overexpression mediated cleaved caspase 3. 
The overall conclusions of this dissertation are that p21 regulates multiple 
responses in the face of stress, including its classical role of halting cell cycle 
progression, activating the PERK arm of the UPR, activating stress kinases and 
FOXO1, impairing GSIS, and reducing insulin signaling and cell survival 
responses. However, future experiments need to determine the exact 
mechanism by which p21 intereferes with these signaling events. It would be 
ideal to do a rapid knockdown study of each signaling intermediate and 
determine whether deleterious effects of p21 are still observed. Signaling 
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intermediates would include those involved in insulin signaling, the UPR, MAPK 
pathways, Akt/mTOR pathways, FOXO-1 pathways, and the mitochondrial 
intrinsic apoptotic pathway. Furthermore, studies on how p21 directly acts on 
these intermediates is needed. For example, does p21 bind and inhibit these 
intermediates? What is the mode of action by which p21 regulates expression or 
phosphorylation of these proteins? 
Given that deleterious effects on beta cells were observed in my project, 
p21 may be a new target to further examine to prevent diabetes. It would be 
interesting, however, to examine whether p21 plays a similar role in these 
processes in islets of donors with other forms of diabetes, such as type 1 
diabetes or gestational diabetes. ER stress is also a postulated mechanism that 
is thought to be involved in the progression of type 1 diabetes (Marhfour et al. 
2012, Hopfgarten et al. 2014), and thus p21 may also be induced in these islets. 
If so, this further validates the necessity for making a p21 inhibitor that 
specifically targets the beta cell. Currently, there is no selective inhibitor of p21, 
and even more challenging is creating a beta cell-specific targeting drug. 
However, there are current tools, such as bioengineered linking of two hormones, 
that are now exploited in hopes to create such drugs and improve targeted 
delivery (Finan et al. 2012).  As alternative, one can envision targeting the 
deleterious targets of p21 itself (e.g., blocking or restoring the mechanism of how 
p21 inhibits insulin secretion and signaling). 
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V.B.  Future Studies 
Future studies that need further investigation that are directly related to 
this project are the effects that p21 had on p-eIF2α, due to the fact that the UPR 
is known to mediate cell cycle arrest, and the activation of eIF2α leads to 
attenuation of translation. However, in this case we observed that the cell cycle 
inhibitor is mediating eIF2α activation. This brings a couple questions to mind: is 
it possible that p21 overexpression will lead to the inhibition of global translation 
as well? Or alternatively, is phosphorylation of eIF2α after p21 overexpression a 
potential negative feedback mechanism to protect the cell from producing too 
much p21? The expression of proteins involved in the cell cycle machinery during 
stress must be tightly regulated in order to prevent mutations and cancerous 
growths. Therefore, p21’s effect on eIF2α could be a mechanism tying in the 
levels of cell cycle regulators to the translation machinery. In other words, signals 
that halt the cell cycle could be activating the UPR as a signal that there is a 
problem with the production of proteins. 
Another question to consider is whether p21 is negatively affecting insulin 
protein translation or folding and whether this is the cause for the increase in 
phosphorylated eIF2α under conditions of p21 overexpression. If p21’s main 
action is to inhibit homeostatic levels of insulin, it could be the main mechanism 
by which beta cell death is occurring. Insulin directly acts on beta cells for cell 
survival. Therefore, with a decrease in insulin production and GSIS, is p21 
overexpression diminishing the necessary beta cell survival signals from insulin? 
Future studies should undergo insulin restoration during conditions of p21 
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overexpression to examine whether p21-mediated cell death is diminished and 
insulin signaling restored. 
Lastly, experiments utilizing p21 knockout mice in conditions of high fat 
diet should be used to recapitulate the same conclusions that were determined 
from in vitro glucolipotoxicity experiments. For example, do p21 knockout mice 
fed a high fat diet have improved outcomes on insulin signaling, or death 
compared to WT mice on high fat diet? If so, does this lead to an overall 
improvement in functional beta cell mass? Determining whether knocking out p21 
is beneficial in terms of functional beta cell mass will help us determine whether 
future clinical studies should be performed using p21 inhibitors. 
Aside from these prospective studies directly related to my project, 
findings from others have also provoked interest in novel aspects of functional 
beta cell mass. For example, DNA methylation and the epigenetics in islets of 
donors with T2D are differentially expressed, and is even evident with the p21 
loci (Dayeh et al. 2014). Further extension of understanding the epigenetic 
regulation in different types of diabetes could give further insight as to how 
functional beta cell mass is regulated in each disease state, and which signaling 
pathways are causing these changes. Given that epigenetic changes occur even 
before birth, they may be the cause for predisposition to a certain type of 
diabetes and perhaps be one of the emerging fields of interest that will set the 
stage for new and upcoming theories on functional beta cell mass. 
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Madison, WI 
 Institute on Teaching and Mentoring Annual Conference 
October 2010 
Tampa, FL 
 
PROFESSIONAL AFFILIATIONS 
 
 The Endocrine Society, Student Member 
2014-2015 
 American Physiological Society, Student Member          
2011-2014 
 
 
 National Organization for the Professional Advancement of Black 
Chemists and Chemical Engineers, Student Member 
2013-2014 
 Underrepresented Professional and Graduate Student Organization, 
Student Member 
2009-2014 
 Indiana Physiology Society, Student Member      
2010-2014 
 American Association for the Advancement of Science, Student Member 
2011-2013 
 Society for Advancement of Chicanos and Native Americans in Science, 
Life Member                  
2010-2014 
 
PRESENTATIONS     
         
 Poster Presentation 
April 2014 
Experimental Biology 
 Oral Presentation 
April 2014 
Experimental Biology-APS Endocrinology & Metabolism Section Featured 
Topic 
 Research Poster Presentation 
February 2014 
Indiana Biomedical Gateway Program Recruitment Poster Session 
 Oral Presentation 
December 2013 
Metabolism and Islet Biology Seminar Series  
 Oral Presentation 
October 2013 
Indiana University Center for Diabetes Research Seminar Series 
 Poster Presentation 
April 2013 
Experimental Biology 
 Oral Presentation 
February 2013 
3rd Annual Indiana Physiological Society Meeting  
 Thesis Proposal Oral Presentation  
February 2013 
Department of Cellular & Integrative Physiology Seminar Series 
 Research Poster Presentation 
February 2013 
Indiana Biomedical Gateway Program Recruitment Poster Session 
 Oral Presentation 
October 2012 
 
 
SACNAS National Conference 
 Poster Presentation 
May 2012 
Midwest Islet Biology Club 5th Annual Meeting 
 Poster Presentation 
November 2011 
NOBCChE Midwest Regional Health Science and BioTechnology 
Conference 
 Research Poster Presentation 
June 2011 
71st Scientific Sessions of the American Diabetes Association 
 
AWARDS   
           
 University of California, San Diego  
2014  
Institutional Research and Academic Career Development Award 
 Indiana University School of Medicine-Physiology Department 
2014 
Dr. Stier Award 
 American Physiological Society-Endocrinology and Metabolism Section 
2014 
Research Recognition Award 
 American Physiological Society 
2014 
Minority Travel Award 
 Indiana Physiological Society’s 3rd Annual Meeting 
2013 
Outstanding Graduate Student Abstract 
 American Physiological Society-Endocrinology and Metabolism Section 
2013 
Virendra B. Mahesh Award of Excellence in Endocrinology 
 Federation of American Societies for Experimental Biology 
2013 
MARC Travel Award 
 IUPUI Graduate and Professional Student Government      
2013 
Educational Enhancement Grant  
 American Physiological Society 
2013 
Minority Travel Award 
 Federation of American Societies for Experimental Biology 
2012 
MARC Travel Award 
 
 
 
 
 IUPUI Graduate and Professional Student Government 
2011 
Educational Enhancement Grant 
 IUPUI Graduate and Professional Student Government 
2011 
C3 Outstanding Service to Career, Campus and Community Award 
        
 
TRAINING EXPERIENCES   
         
Indiana University School of Medicine     
August 2009-September 2014 
Department of Cellular and Integrative Physiology 
Mentor: Patrick T. Fueger, Ph.D.  
 
California State University, Los Angeles    
August 2007-September 2009 
Department of Biological Sciences 
Mentor: Amelia Russo-Neustadt, Ph.D.     
 
University of California, Irvine                   
June 2005-June 2007  
Center for the Neurobiology of Learning and Memory  
Mentor: James McGaugh, Ph.D. and Benno Roozendaal, Ph.D.  
 
TEACHING EXPERIENCE 
 
Indiana University School of Medicine                
F503-Human Physiology  
November 2013 
Guest Lecturer: “GI motility, chewing, swallowing” and “The Stomach”  
 
Martin University                            
Human Anatomy and Physiology 
February 2013 
Guest Lecturer: “The Endocrine System” 
 
Indiana University Brain Link/MASH (K-12) Science Summer Program 
Spanish Enrichment Program 
July 2011 
Enrichment Program Facilitator: “Spanish” 
 
California State University, Los Angeles 
Animal Biology 
January 2009-June 2009 
Lab instructor 
 
 
PROFESSIONAL AND UNIVERSITY SERVICE 
        
 Board of Directors, Graduate Student Member, Society for the 
Advancement of Chicanos and Native Americans in Science 
2014-2016 
 Trainee Advisory Committee, Teaching Section Representative, American 
Physiological Society 
2014-2017  
 Executive Board Member, Treasurer, Underrepresented Professional and 
Graduate Student Organization 
2012-2014 
 Preparing Future Faculty Mentor Program 
2011-2014 
 Indiana University School of Medicine Student Mentor 
2010-2014 
 Graduate and Professional Student Government        
2013-2014 
IU School of Medicine Representative  
 Indiana Physiological Society              
2014 
Abstract Reviewer   
 Indiana University School of Medicine Graduate Committee                 
2013-2014 
Student Representative 
 Indiana University School of Medicine Student Ambassador 
2010-2014 
Student Coordinator for Campus Visits 
 Indiana University School of Medicine Getting You into IUPUI  
2010-2014 
Student Ambassador 
 IUPUI Preparing Future Faculty and Professionals 
2012 
Session Moderator, “Of Color in the Academy” 
 Wells Center Molecular Medicine in Action 
2010-2014 
Team Member, “Dissecting Diabetes Module” 
 IU Biomedical Gateway Ph.D. Program Diversity Committee 
2009-2013 
Student Representative 
 
